[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0Kf42r3-ZxB6BLaBE3YXfLRGBflGSUuIjMOmG5vam9A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":81,"rows":88},"Seoul National University Bundang Hospital",[4],366,false,51,22,1163152,39,213,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Stroke",15,{"name":18,"count":19},"Gastric Cancer",14,{"name":21,"count":22},"Diabetes",11,{"name":24,"count":25},"Type 2 Diabetes",8,{"name":27,"count":25},"Neuromuscular Blockade",{"name":29,"count":25},"Coronary Artery Disease",{"name":31,"count":32},"Helicobacter Pylori Infection",7,{"name":34,"count":32},"Hypertension",[36,41,46,51,56,61,65,69,73,77],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07196449","Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects","2025-06-09","Methotrexate",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06846411","The EMPA-FIT Study","2025-09-30","Empagliflozin 10 mg",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05525858","KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II","2026-09","Alectinib",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06382493","Tegoprazan-containing Sequential for H. Pylori","2026-12-12","Tegoprazan-containing sequential H. pylori eradication therapy",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06399835","Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis","2026-12-31","Enavogliflozin",{"nctId":62,"briefTitle":63,"date":59,"intervention":64},"NCT05365438","Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Omega 3-Atorvastatin",{"nctId":66,"briefTitle":67,"date":59,"intervention":68},"NCT06402747","Clopidogrel Versus Cilostazol on Vessels","Clopidogrel",{"nctId":70,"briefTitle":71,"date":59,"intervention":72},"NCT06989697","Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes","Cilostazol \u002F Ginko Leaf Dried Ext.",{"nctId":74,"briefTitle":75,"date":59,"intervention":76},"NCT05365425","Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","Choline fenofibrate",{"nctId":78,"briefTitle":79,"date":59,"intervention":80},"NCT06989723","Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes","Pioglitazone 15 MG [Actos]",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,139,172,208,238,268,286,309,327,349,367,390,408,426,447,475,493,517,554,572,590,615,636,654,686,704,722,740,758,776,794,812,830,859,877,895,913,939,965,983,1020,1061,1102,1140,1162,1191,1231,1253,1279,1297,1323,1347,1369,1387,1413,1431,1457,1475,1493,1520,1538,1564,1588,1612,1637,1664,1682,1708,1726,1753,1771,1789,1813,1838,1863,1890,1908,1934,1952,1970,1993,2011,2029,2047,2072,2090,2117,2140,2165,2191,2218,2236,2254,2282,2306,2331,2355,2382,2400,2418,2443,2461,2479,2504,2531,2557,2581,2599,2626,2668,2691,2716,2734,2761,2786,2804,2828,2846,2871,2889,2913,2931,3056,3163,3219,3265,3317,3347,3378,3404,3430,3465,3493,3520,3553,3587,3609,3643,3665,3697,3719,3748,3770,3792,3814,3838,3866,3884,3902,3920,3942,3966,3984,4002,4020,4045,4063,4086,4112,4130,4155,4173,4191,4214,4237,4261,4285,4303,4321,4344,4367,4393,4411,4441,4459,4485,4503,4521,4539,4557,4581,4599,4617,4635,4661,4679,4703,4726,4744,4769,4787,4811,4835,4858,4882,4900,4923,4941,4965,4992,5010,5028,5052,5070,5092,5115,5133],{"intervention":90,"totalTrials":91,"cells":92},"Cilostazol",3,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":113,"NA":137},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT02266030","Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM","COMPLETED",[85],"2016-11","2011-02",100,[29],[90,112],"Aspirin",{"trials":114,"activeCount":136,"soonestReadout":59},[115,124],{"nctId":66,"briefTitle":67,"status":116,"phases":117,"primaryCompletion":59,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"RECRUITING",[86],"2027-01-31","2024-04-16",120,[24,122],"Atherosclerosis",[68,90],{"nctId":125,"briefTitle":126,"status":105,"phases":127,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":135},"NCT03248401","Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes",[86],"2018-10-21","2019-12-31","2016-09-26",50,[133,134],"Type 2 Diabetes Mellitus","Carotid Atherosclerosis",[90,112],1,{"trials":138,"activeCount":95},[],{"intervention":140,"totalTrials":141,"cells":142},"Pioglitazone",2,{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":170},{"trials":144,"activeCount":95},[],{"trials":146,"activeCount":95},[],{"trials":148,"activeCount":95},[],{"trials":150,"activeCount":95},[],{"trials":152,"activeCount":136,"soonestReadout":59},[153,159],{"nctId":57,"briefTitle":58,"status":116,"phases":154,"primaryCompletion":59,"completion":155,"start":156,"enrollment":120,"conditions":157,"interventions":158},[86],"2027-12-31","2024-02-01",[24],[60,140],{"nctId":160,"briefTitle":161,"status":162,"phases":163,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":167,"interventions":168},"NCT02315287","Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","UNKNOWN",[86],"2021-12-31","2014-09",190,[24],[140,169],"Lobeglitazone",{"trials":171,"activeCount":95},[],{"intervention":45,"totalTrials":141,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":206},{"trials":175,"activeCount":95},[],{"trials":177,"activeCount":95},[],{"trials":179,"activeCount":95},[],{"trials":181,"activeCount":95},[],{"trials":183,"activeCount":136,"soonestReadout":44},[184,193],{"nctId":42,"briefTitle":43,"status":116,"phases":185,"primaryCompletion":44,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":191},[86],"2025-12-31","2024-01-01",46,[21,190],"Diabetes Mellitus, Type II",[45,192],"Metformin",{"nctId":194,"briefTitle":195,"status":162,"phases":196,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":203},"NCT03877406","Effect of Empagliflozin on Body Composition and Ketones",[86],"2023-12-31","2018-08-01",200,[201,202],"Diabetes Mellitus","Fat; Intolerance, Pancreas",[204,205],"Empagliflozin 10 MG","Hypoglycemics",{"trials":207,"activeCount":95},[],{"intervention":192,"totalTrials":141,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":236},{"trials":211,"activeCount":95},[],{"trials":213,"activeCount":95},[],{"trials":215,"activeCount":95},[],{"trials":217,"activeCount":95},[],{"trials":219,"activeCount":136,"soonestReadout":44},[220,224],{"nctId":42,"briefTitle":43,"status":116,"phases":221,"primaryCompletion":44,"completion":186,"start":187,"enrollment":188,"conditions":222,"interventions":223},[86],[21,190],[45,192],{"nctId":225,"briefTitle":226,"status":105,"phases":227,"primaryCompletion":228,"completion":164,"start":229,"enrollment":230,"conditions":231,"interventions":232},"NCT02338921","Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy",[86],"2021-11-30","2015-01",78,[24],[233,234,169,235,192],"Sitagliptin","Dapagliflozin","Glimepirde",{"trials":237,"activeCount":95},[],{"intervention":68,"totalTrials":141,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":260,"NA":266},{"trials":241,"activeCount":95},[],{"trials":243,"activeCount":95},[],{"trials":245,"activeCount":95},[],{"trials":247,"activeCount":95},[248],{"nctId":249,"briefTitle":250,"status":105,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":258},"NCT02294643","Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study",[85],"2012-03","2014-03","2009-04",220,[29,201,257],"Renal Insufficiency, Chronic",[259,112,68],"Sarpogrelate",{"trials":261,"activeCount":136,"soonestReadout":59},[262],{"nctId":66,"briefTitle":67,"status":116,"phases":263,"primaryCompletion":59,"completion":118,"start":119,"enrollment":120,"conditions":264,"interventions":265},[86],[24,122],[68,90],{"trials":267,"activeCount":95},[],{"intervention":60,"totalTrials":136,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":284},{"trials":271,"activeCount":95},[],{"trials":273,"activeCount":95},[],{"trials":275,"activeCount":95},[],{"trials":277,"activeCount":95},[],{"trials":279,"activeCount":136,"soonestReadout":59},[280],{"nctId":57,"briefTitle":58,"status":116,"phases":281,"primaryCompletion":59,"completion":155,"start":156,"enrollment":120,"conditions":282,"interventions":283},[86],[24],[60,140],{"trials":285,"activeCount":95},[],{"intervention":64,"totalTrials":136,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":307},{"trials":289,"activeCount":95},[],{"trials":291,"activeCount":95},[],{"trials":293,"activeCount":95},[],{"trials":295,"activeCount":95},[],{"trials":297,"activeCount":136,"soonestReadout":59},[298],{"nctId":62,"briefTitle":63,"status":116,"phases":299,"primaryCompletion":59,"completion":59,"start":300,"enrollment":301,"conditions":302,"interventions":305},[86],"2022-10-01",105,[303,122,304],"Dyslipidemias","Diabetes Mellitus, Type 2",[64,64,306],"Atorvastatin-Ezetimibe",{"trials":308,"activeCount":95},[],{"intervention":306,"totalTrials":136,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":325},{"trials":312,"activeCount":95},[],{"trials":314,"activeCount":95},[],{"trials":316,"activeCount":95},[],{"trials":318,"activeCount":95},[],{"trials":320,"activeCount":136,"soonestReadout":59},[321],{"nctId":62,"briefTitle":63,"status":116,"phases":322,"primaryCompletion":59,"completion":59,"start":300,"enrollment":301,"conditions":323,"interventions":324},[86],[303,122,304],[64,64,306],{"trials":326,"activeCount":95},[],{"intervention":76,"totalTrials":136,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":335,"PHASE4":337,"NA":347},{"trials":330,"activeCount":95},[],{"trials":332,"activeCount":95},[],{"trials":334,"activeCount":95},[],{"trials":336,"activeCount":95},[],{"trials":338,"activeCount":136,"soonestReadout":59},[339],{"nctId":74,"briefTitle":75,"status":116,"phases":340,"primaryCompletion":59,"completion":155,"start":341,"enrollment":342,"conditions":343,"interventions":345},[86],"2023-06-01",56,[344,122,304],"Dyslipidemia",[76,346],"Policosanol",{"trials":348,"activeCount":95},[],{"intervention":346,"totalTrials":136,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":365},{"trials":352,"activeCount":95},[],{"trials":354,"activeCount":95},[],{"trials":356,"activeCount":95},[],{"trials":358,"activeCount":95},[],{"trials":360,"activeCount":136,"soonestReadout":59},[361],{"nctId":74,"briefTitle":75,"status":116,"phases":362,"primaryCompletion":59,"completion":155,"start":341,"enrollment":342,"conditions":363,"interventions":364},[86],[344,122,304],[76,346],{"trials":366,"activeCount":95},[],{"intervention":80,"totalTrials":136,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":388},{"trials":370,"activeCount":95},[],{"trials":372,"activeCount":95},[],{"trials":374,"activeCount":95},[],{"trials":376,"activeCount":95},[],{"trials":378,"activeCount":136,"soonestReadout":59},[379],{"nctId":78,"briefTitle":79,"status":116,"phases":380,"primaryCompletion":59,"completion":381,"start":382,"enrollment":120,"conditions":383,"interventions":385},[86],"2027-06-30","2025-01-01",[24,384],"Fatty Liver",[80,386,387],"Empagliflozin 10 MG [Jardiance]","Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]",{"trials":389,"activeCount":95},[],{"intervention":386,"totalTrials":136,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":398,"PHASE4":400,"NA":406},{"trials":393,"activeCount":95},[],{"trials":395,"activeCount":95},[],{"trials":397,"activeCount":95},[],{"trials":399,"activeCount":95},[],{"trials":401,"activeCount":136,"soonestReadout":59},[402],{"nctId":78,"briefTitle":79,"status":116,"phases":403,"primaryCompletion":59,"completion":381,"start":382,"enrollment":120,"conditions":404,"interventions":405},[86],[24,384],[80,386,387],{"trials":407,"activeCount":95},[],{"intervention":387,"totalTrials":136,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":424},{"trials":411,"activeCount":95},[],{"trials":413,"activeCount":95},[],{"trials":415,"activeCount":95},[],{"trials":417,"activeCount":95},[],{"trials":419,"activeCount":136,"soonestReadout":59},[420],{"nctId":78,"briefTitle":79,"status":116,"phases":421,"primaryCompletion":59,"completion":381,"start":382,"enrollment":120,"conditions":422,"interventions":423},[86],[24,384],[80,386,387],{"trials":425,"activeCount":95},[],{"intervention":72,"totalTrials":136,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":443,"NA":445},{"trials":429,"activeCount":95},[],{"trials":431,"activeCount":95},[],{"trials":433,"activeCount":95},[],{"trials":435,"activeCount":136,"soonestReadout":59},[436],{"nctId":70,"briefTitle":71,"status":116,"phases":437,"primaryCompletion":59,"completion":381,"start":382,"enrollment":438,"conditions":439,"interventions":442},[85],80,[440,441],"Type 2 Diabets Mellitus","Cognitive Ability, General",[72],{"trials":444,"activeCount":95},[],{"trials":446,"activeCount":95},[],{"intervention":448,"totalTrials":136,"cells":449},"Oxaliplatin, 5FU, leucovorin",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":469,"PHASE4":471,"NA":473},{"trials":451,"activeCount":95},[],{"trials":453,"activeCount":95},[],{"trials":455,"activeCount":136,"soonestReadout":461},[456],{"nctId":457,"briefTitle":458,"status":459,"phases":460,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":467},"NCT07062536","mFOLFOX\u002FmFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","NOT_YET_RECRUITING",[84],"2027-04-01","2028-04-01","2026-06-01",130,[466],"Biliary Cancer Metastatic",[448,468],"Oxaliplatin, 5FU, leucovorin\u002FIrinotecan , 5FU, leucovorin,",{"trials":470,"activeCount":95},[],{"trials":472,"activeCount":95},[],{"trials":474,"activeCount":95},[],{"intervention":468,"totalTrials":136,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":478,"activeCount":95},[],{"trials":480,"activeCount":95},[],{"trials":482,"activeCount":136,"soonestReadout":461},[483],{"nctId":457,"briefTitle":458,"status":459,"phases":484,"primaryCompletion":461,"completion":462,"start":463,"enrollment":464,"conditions":485,"interventions":486},[84],[466],[448,468],{"trials":488,"activeCount":95},[],{"trials":490,"activeCount":95},[],{"trials":492,"activeCount":95},[],{"intervention":494,"totalTrials":136,"cells":495},"lenalidomide",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":511,"PHASE4":513,"NA":515},{"trials":497,"activeCount":95},[],{"trials":499,"activeCount":95},[],{"trials":501,"activeCount":136,"soonestReadout":461},[502],{"nctId":503,"briefTitle":504,"status":116,"phases":505,"primaryCompletion":461,"completion":462,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT05260619","Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma",[84],"2022-04-01",28,[509],"Central Nervous System Lymphoma",[494],{"trials":512,"activeCount":95},[],{"trials":514,"activeCount":95},[],{"trials":516,"activeCount":95},[],{"intervention":518,"totalTrials":141,"cells":519},"Rifampicin",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":521,"activeCount":95},[],{"trials":523,"activeCount":136,"soonestReadout":39},[524,536],{"nctId":525,"briefTitle":526,"status":162,"phases":527,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT06108453","A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects",[83],"2024-10-24","2024-11-24","2023-08-21",10,[533],"Drug Interactions",[535,518],"Methotrexate Sodium",{"nctId":37,"briefTitle":38,"status":537,"phases":538,"primaryCompletion":39,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":544},"ACTIVE_NOT_RECRUITING",[83],"2026-04-14","2025-05-14",12,[543],"Drug Drug Interaction (DDI)",[40,518,545],"Cyclosporine",{"trials":547,"activeCount":95},[],{"trials":549,"activeCount":95},[],{"trials":551,"activeCount":95},[],{"trials":553,"activeCount":95},[],{"intervention":40,"totalTrials":136,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":570},{"trials":557,"activeCount":95},[],{"trials":559,"activeCount":136,"soonestReadout":39},[560],{"nctId":37,"briefTitle":38,"status":537,"phases":561,"primaryCompletion":39,"completion":539,"start":540,"enrollment":541,"conditions":562,"interventions":563},[83],[543],[40,518,545],{"trials":565,"activeCount":95},[],{"trials":567,"activeCount":95},[],{"trials":569,"activeCount":95},[],{"trials":571,"activeCount":95},[],{"intervention":545,"totalTrials":136,"cells":573},{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":582,"PHASE3":584,"PHASE4":586,"NA":588},{"trials":575,"activeCount":95},[],{"trials":577,"activeCount":136,"soonestReadout":39},[578],{"nctId":37,"briefTitle":38,"status":537,"phases":579,"primaryCompletion":39,"completion":539,"start":540,"enrollment":541,"conditions":580,"interventions":581},[83],[543],[40,518,545],{"trials":583,"activeCount":95},[],{"trials":585,"activeCount":95},[],{"trials":587,"activeCount":95},[],{"trials":589,"activeCount":95},[],{"intervention":591,"totalTrials":136,"cells":592},"Levothyroxine tapering",{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":603},{"trials":594,"activeCount":95},[],{"trials":596,"activeCount":95},[],{"trials":598,"activeCount":95},[],{"trials":600,"activeCount":95},[],{"trials":602,"activeCount":95},[],{"trials":604,"activeCount":136,"soonestReadout":609},[605],{"nctId":606,"briefTitle":607,"status":116,"phases":608,"primaryCompletion":609,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":614},"NCT07421869","SNUH Immune Checkpoint Inhibitor-induced Hypothyroidism Recovery Trial",[87],"2029-03-04","2024-06-12",107,[613],"Hypothyroidism",[591],{"intervention":55,"totalTrials":136,"cells":616},{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":618,"activeCount":95},[],{"trials":620,"activeCount":95},[],{"trials":622,"activeCount":95},[],{"trials":624,"activeCount":95},[],{"trials":626,"activeCount":95},[],{"trials":628,"activeCount":136,"soonestReadout":54},[629],{"nctId":52,"briefTitle":53,"status":116,"phases":630,"primaryCompletion":54,"completion":54,"start":631,"enrollment":632,"conditions":633,"interventions":634},[87],"2021-02-01",400,[31],[55,635],"Esomeprazole-containing sequential H. pylori eradication therapy",{"intervention":635,"totalTrials":136,"cells":637},{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":639,"activeCount":95},[],{"trials":641,"activeCount":95},[],{"trials":643,"activeCount":95},[],{"trials":645,"activeCount":95},[],{"trials":647,"activeCount":95},[],{"trials":649,"activeCount":136,"soonestReadout":54},[650],{"nctId":52,"briefTitle":53,"status":116,"phases":651,"primaryCompletion":54,"completion":54,"start":631,"enrollment":632,"conditions":652,"interventions":653},[87],[31],[55,635],{"intervention":50,"totalTrials":136,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":666},{"trials":657,"activeCount":95},[],{"trials":659,"activeCount":95},[],{"trials":661,"activeCount":95},[],{"trials":663,"activeCount":95},[],{"trials":665,"activeCount":95},[],{"trials":667,"activeCount":136,"soonestReadout":49},[668],{"nctId":47,"briefTitle":48,"status":116,"phases":669,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":677},[],"2027-03","2022-09-28",1000,[674,675,676],"Solid Tumor","Advanced Solid Tumor","Metastatic Cancer",[50,678,679,680,681,682,683,684,685],"Atezolizumab","Erlotinib","Trastuzumab + Pertuzumab","Trastuzumab emtansine","Vemurafenib","Bevacizumab + Erlotinib","Entrectinib","Pralsetinib",{"intervention":678,"totalTrials":136,"cells":687},{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":698},{"trials":689,"activeCount":95},[],{"trials":691,"activeCount":95},[],{"trials":693,"activeCount":95},[],{"trials":695,"activeCount":95},[],{"trials":697,"activeCount":95},[],{"trials":699,"activeCount":136,"soonestReadout":49},[700],{"nctId":47,"briefTitle":48,"status":116,"phases":701,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":702,"interventions":703},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":679,"totalTrials":136,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":716},{"trials":707,"activeCount":95},[],{"trials":709,"activeCount":95},[],{"trials":711,"activeCount":95},[],{"trials":713,"activeCount":95},[],{"trials":715,"activeCount":95},[],{"trials":717,"activeCount":136,"soonestReadout":49},[718],{"nctId":47,"briefTitle":48,"status":116,"phases":719,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":720,"interventions":721},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":680,"totalTrials":136,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":725,"activeCount":95},[],{"trials":727,"activeCount":95},[],{"trials":729,"activeCount":95},[],{"trials":731,"activeCount":95},[],{"trials":733,"activeCount":95},[],{"trials":735,"activeCount":136,"soonestReadout":49},[736],{"nctId":47,"briefTitle":48,"status":116,"phases":737,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":738,"interventions":739},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":681,"totalTrials":136,"cells":741},{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":752},{"trials":743,"activeCount":95},[],{"trials":745,"activeCount":95},[],{"trials":747,"activeCount":95},[],{"trials":749,"activeCount":95},[],{"trials":751,"activeCount":95},[],{"trials":753,"activeCount":136,"soonestReadout":49},[754],{"nctId":47,"briefTitle":48,"status":116,"phases":755,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":756,"interventions":757},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":682,"totalTrials":136,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":761,"activeCount":95},[],{"trials":763,"activeCount":95},[],{"trials":765,"activeCount":95},[],{"trials":767,"activeCount":95},[],{"trials":769,"activeCount":95},[],{"trials":771,"activeCount":136,"soonestReadout":49},[772],{"nctId":47,"briefTitle":48,"status":116,"phases":773,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":774,"interventions":775},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":683,"totalTrials":136,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":788},{"trials":779,"activeCount":95},[],{"trials":781,"activeCount":95},[],{"trials":783,"activeCount":95},[],{"trials":785,"activeCount":95},[],{"trials":787,"activeCount":95},[],{"trials":789,"activeCount":136,"soonestReadout":49},[790],{"nctId":47,"briefTitle":48,"status":116,"phases":791,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":792,"interventions":793},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":684,"totalTrials":136,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":797,"activeCount":95},[],{"trials":799,"activeCount":95},[],{"trials":801,"activeCount":95},[],{"trials":803,"activeCount":95},[],{"trials":805,"activeCount":95},[],{"trials":807,"activeCount":136,"soonestReadout":49},[808],{"nctId":47,"briefTitle":48,"status":116,"phases":809,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":810,"interventions":811},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":685,"totalTrials":136,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":815,"activeCount":95},[],{"trials":817,"activeCount":95},[],{"trials":819,"activeCount":95},[],{"trials":821,"activeCount":95},[],{"trials":823,"activeCount":95},[],{"trials":825,"activeCount":136,"soonestReadout":49},[826],{"nctId":47,"briefTitle":48,"status":116,"phases":827,"primaryCompletion":49,"completion":670,"start":671,"enrollment":672,"conditions":828,"interventions":829},[],[674,675,676],[50,678,679,680,681,682,683,684,685],{"intervention":831,"totalTrials":136,"cells":832},"10 day sequential therapy",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":843},{"trials":834,"activeCount":95},[],{"trials":836,"activeCount":95},[],{"trials":838,"activeCount":95},[],{"trials":840,"activeCount":95},[],{"trials":842,"activeCount":95},[],{"trials":844,"activeCount":136,"soonestReadout":849},[845],{"nctId":846,"briefTitle":847,"status":116,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT02373280","The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection",[87],"2027-04","2027-12","2014-08",600,[854],"Helicobacter Infection",[831,856,857,858],"7 day tailored PPI triple therapy","7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]","7 or 14 days tailored EBMT therapy group",{"intervention":856,"totalTrials":136,"cells":860},{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":869,"NA":871},{"trials":862,"activeCount":95},[],{"trials":864,"activeCount":95},[],{"trials":866,"activeCount":95},[],{"trials":868,"activeCount":95},[],{"trials":870,"activeCount":95},[],{"trials":872,"activeCount":136,"soonestReadout":849},[873],{"nctId":846,"briefTitle":847,"status":116,"phases":874,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":875,"interventions":876},[87],[854],[831,856,857,858],{"intervention":857,"totalTrials":136,"cells":878},{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":889},{"trials":880,"activeCount":95},[],{"trials":882,"activeCount":95},[],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[],{"trials":888,"activeCount":95},[],{"trials":890,"activeCount":136,"soonestReadout":849},[891],{"nctId":846,"briefTitle":847,"status":116,"phases":892,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":893,"interventions":894},[87],[854],[831,856,857,858],{"intervention":858,"totalTrials":136,"cells":896},{"EARLY_PHASE1":897,"PHASE1":899,"PHASE2":901,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":898,"activeCount":95},[],{"trials":900,"activeCount":95},[],{"trials":902,"activeCount":95},[],{"trials":904,"activeCount":95},[],{"trials":906,"activeCount":95},[],{"trials":908,"activeCount":136,"soonestReadout":849},[909],{"nctId":846,"briefTitle":847,"status":116,"phases":910,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":911,"interventions":912},[87],[854],[831,856,857,858],{"intervention":914,"totalTrials":136,"cells":915},"levothyroxine",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":926},{"trials":917,"activeCount":95},[],{"trials":919,"activeCount":95},[],{"trials":921,"activeCount":95},[],{"trials":923,"activeCount":95},[],{"trials":925,"activeCount":95},[],{"trials":927,"activeCount":136,"soonestReadout":932},[928],{"nctId":929,"briefTitle":930,"status":116,"phases":931,"primaryCompletion":932,"completion":933,"start":934,"enrollment":935,"conditions":936,"interventions":938},"NCT07380854","Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism",[87],"2032-02-26","2037-02-26","2022-02-27",338,[937],"Subclinical Hypothyroidism",[914],{"intervention":940,"totalTrials":136,"cells":941},"Furosemide",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":943,"activeCount":95},[],{"trials":945,"activeCount":95},[],{"trials":947,"activeCount":95},[],{"trials":949,"activeCount":95},[],{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":136,"soonestReadout":958},[954],{"nctId":955,"briefTitle":956,"status":116,"phases":957,"primaryCompletion":958,"completion":958,"start":959,"enrollment":166,"conditions":960,"interventions":963},"NCT07550790","Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure",[87],"2029-01-30","2026-05-01",[961,962],"Heart Failure Acute","Renal Dysfunction",[940,964],"0.9 % Normal Saline",{"intervention":964,"totalTrials":136,"cells":966},{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":968,"activeCount":95},[],{"trials":970,"activeCount":95},[],{"trials":972,"activeCount":95},[],{"trials":974,"activeCount":95},[],{"trials":976,"activeCount":95},[],{"trials":978,"activeCount":136,"soonestReadout":958},[979],{"nctId":955,"briefTitle":956,"status":116,"phases":980,"primaryCompletion":958,"completion":958,"start":959,"enrollment":166,"conditions":981,"interventions":982},[87],[961,962],[940,964],{"intervention":112,"totalTrials":984,"cells":985},4,{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":1002,"NA":1018},{"trials":987,"activeCount":95},[],{"trials":989,"activeCount":95},[],{"trials":991,"activeCount":95},[],{"trials":993,"activeCount":95},[994,998],{"nctId":249,"briefTitle":250,"status":105,"phases":995,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":996,"interventions":997},[85],[29,201,257],[259,112,68],{"nctId":103,"briefTitle":104,"status":105,"phases":999,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":1000,"interventions":1001},[85],[29],[90,112],{"trials":1003,"activeCount":95},[1004,1014],{"nctId":1005,"briefTitle":1006,"status":105,"phases":1007,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1013},"NCT02607436","Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease",[86],"2016-02","2016-04","2015-07",40,[29],[259,112],{"nctId":125,"briefTitle":126,"status":105,"phases":1015,"primaryCompletion":128,"completion":129,"start":130,"enrollment":131,"conditions":1016,"interventions":1017},[86],[133,134],[90,112],{"trials":1019,"activeCount":95},[],{"intervention":233,"totalTrials":91,"cells":1021},{"EARLY_PHASE1":1022,"PHASE1":1024,"PHASE2":1026,"PHASE3":1028,"PHASE4":1041,"NA":1059},{"trials":1023,"activeCount":95},[],{"trials":1025,"activeCount":95},[],{"trials":1027,"activeCount":95},[],{"trials":1029,"activeCount":95},[1030],{"nctId":1031,"briefTitle":1032,"status":105,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":1038,"interventions":1039},"NCT03076112","Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin",[85],"2022-06-30","2022-08-31","2017-04-25",170,[133],[1040,233],"Ipragliflozin",{"trials":1042,"activeCount":95},[1043,1055],{"nctId":1044,"briefTitle":1045,"status":105,"phases":1046,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1051,"interventions":1052},"NCT01100125","Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment",[86],"2012-01","2012-11","2010-04",140,[21],[1053,1054],"sitagliptin","insulin dose increase",{"nctId":225,"briefTitle":226,"status":105,"phases":1056,"primaryCompletion":228,"completion":164,"start":229,"enrollment":230,"conditions":1057,"interventions":1058},[86],[24],[233,234,169,235,192],{"trials":1060,"activeCount":95},[],{"intervention":1062,"totalTrials":141,"cells":1063},"Remimazolam besylate",{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1100},{"trials":1065,"activeCount":95},[],{"trials":1067,"activeCount":95},[],{"trials":1069,"activeCount":95},[],{"trials":1071,"activeCount":95},[],{"trials":1073,"activeCount":95},[1074,1088],{"nctId":1075,"briefTitle":1076,"status":105,"phases":1077,"primaryCompletion":1078,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1087},"NCT05486377","Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia",[86],"2023-05-19","2022-08-02",96,[1082,1083,1084,1085,1086],"Remimazolam","Desflurane","Cryoablation","Arrhythmia","General Anesthesia",[1062],{"nctId":1089,"briefTitle":1090,"status":162,"phases":1091,"primaryCompletion":1092,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1099},"NCT05856617","Remimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients",[86],"2023-08-30","2023-09-12","2022-10-25",88,[1082,1083,1097,1098,1086],"Morbid Obesity","Sleeve Gastrectomy",[1062],{"trials":1101,"activeCount":95},[],{"intervention":1103,"totalTrials":141,"cells":1104},"Gemigliptin",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1126,"NA":1138},{"trials":1106,"activeCount":95},[],{"trials":1108,"activeCount":95},[],{"trials":1110,"activeCount":95},[],{"trials":1112,"activeCount":95},[1113],{"nctId":1114,"briefTitle":1115,"status":162,"phases":1116,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1124},"NCT02250872","Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury",[84,85],"2018-02","2018-06","2014-12",182,[1122,1123],"Cancer","Cisplatin Adverse Reaction",[1103,1125],"Cisplatin",{"trials":1127,"activeCount":95},[1128],{"nctId":1129,"briefTitle":1130,"status":162,"phases":1131,"primaryCompletion":1132,"completion":197,"start":1133,"enrollment":438,"conditions":1134,"interventions":1136},"NCT05663736","Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes",[86],"2023-10-31","2020-01-01",[1135],"Ejection Fraction",[1103,1137],"Glimepiride",{"trials":1139,"activeCount":95},[],{"intervention":259,"totalTrials":141,"cells":1141},{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1154,"NA":1160},{"trials":1143,"activeCount":95},[],{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[],{"trials":1149,"activeCount":95},[1150],{"nctId":249,"briefTitle":250,"status":105,"phases":1151,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":1152,"interventions":1153},[85],[29,201,257],[259,112,68],{"trials":1155,"activeCount":95},[1156],{"nctId":1005,"briefTitle":1006,"status":105,"phases":1157,"primaryCompletion":1008,"completion":1009,"start":1010,"enrollment":1011,"conditions":1158,"interventions":1159},[86],[29],[259,112],{"trials":1161,"activeCount":95},[],{"intervention":234,"totalTrials":141,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1189},{"trials":1165,"activeCount":95},[],{"trials":1167,"activeCount":95},[],{"trials":1169,"activeCount":95},[],{"trials":1171,"activeCount":95},[],{"trials":1173,"activeCount":95},[1174,1185],{"nctId":1175,"briefTitle":1176,"status":105,"phases":1177,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1183},"NCT02610088","Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide",[86],"2018-07","2018-09","2015-11",32,[21],[234,1184],"Gliclazide",{"nctId":225,"briefTitle":226,"status":105,"phases":1186,"primaryCompletion":228,"completion":164,"start":229,"enrollment":230,"conditions":1187,"interventions":1188},[86],[24],[233,234,169,235,192],{"trials":1190,"activeCount":95},[],{"intervention":1192,"totalTrials":141,"cells":1193},"esomeprazole",{"EARLY_PHASE1":1194,"PHASE1":1196,"PHASE2":1198,"PHASE3":1200,"PHASE4":1202,"NA":1229},{"trials":1195,"activeCount":95},[],{"trials":1197,"activeCount":95},[],{"trials":1199,"activeCount":95},[],{"trials":1201,"activeCount":95},[],{"trials":1203,"activeCount":95},[1204,1215],{"nctId":1205,"briefTitle":1206,"status":105,"phases":1207,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1212},"NCT01887249","15-day Sequential Therapy for Helicobacter Pylori Infection in Korea",[86],"2013-07","2010-05",287,[31],[1213,1214,1192],"Clarithromycin","metronidazole",{"nctId":1216,"briefTitle":1217,"status":105,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT01792700","Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy",[86],"2010-12","2003-01",648,[1223],"Helicobacter Infections",[1192,1225,1214,1226,1227,1228],"tripotassium dicitrate bismuthate","tetracycline","moxifloxacin","amoxicillin",{"trials":1230,"activeCount":95},[],{"intervention":169,"totalTrials":141,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1251},{"trials":1234,"activeCount":95},[],{"trials":1236,"activeCount":95},[],{"trials":1238,"activeCount":95},[],{"trials":1240,"activeCount":95},[],{"trials":1242,"activeCount":95},[1243,1247],{"nctId":225,"briefTitle":226,"status":105,"phases":1244,"primaryCompletion":228,"completion":164,"start":229,"enrollment":230,"conditions":1245,"interventions":1246},[86],[24],[233,234,169,235,192],{"nctId":160,"briefTitle":161,"status":162,"phases":1248,"primaryCompletion":164,"completion":164,"start":165,"enrollment":166,"conditions":1249,"interventions":1250},[86],[24],[140,169],{"trials":1252,"activeCount":95},[],{"intervention":1254,"totalTrials":136,"cells":1255},"Pregabalin 75mg",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1277},{"trials":1257,"activeCount":95},[],{"trials":1259,"activeCount":95},[],{"trials":1261,"activeCount":95},[],{"trials":1263,"activeCount":95},[],{"trials":1265,"activeCount":95},[1266],{"nctId":1267,"briefTitle":1268,"status":162,"phases":1269,"primaryCompletion":1270,"completion":129,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1275},"NCT03584074","Clinical Trial of Pregabalin and COX2 in Spinal Stenosis",[86],"2019-05-30","2018-07-01",60,[1274],"Spinal Stenosis Lumbar",[1254,1276],"Celebrex 200Mg",{"trials":1278,"activeCount":95},[],{"intervention":1276,"totalTrials":136,"cells":1280},{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1289,"NA":1295},{"trials":1282,"activeCount":95},[],{"trials":1284,"activeCount":95},[],{"trials":1286,"activeCount":95},[],{"trials":1288,"activeCount":95},[],{"trials":1290,"activeCount":95},[1291],{"nctId":1267,"briefTitle":1268,"status":162,"phases":1292,"primaryCompletion":1270,"completion":129,"start":1271,"enrollment":1272,"conditions":1293,"interventions":1294},[86],[1274],[1254,1276],{"trials":1296,"activeCount":95},[],{"intervention":1298,"totalTrials":136,"cells":1299},"Biomatrix drug eluting stent",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1321},{"trials":1301,"activeCount":95},[],{"trials":1303,"activeCount":95},[],{"trials":1305,"activeCount":95},[],{"trials":1307,"activeCount":95},[],{"trials":1309,"activeCount":95},[1310],{"nctId":1311,"briefTitle":1312,"status":105,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1320},"NCT02299011","Comparison of Biomatrix and Orsiro Drug Eluting Stent",[86],"2019-06","2019-09","2014-07",2341,[29,1319],"Myocardial Ischemia",[1298],{"trials":1322,"activeCount":95},[],{"intervention":1324,"totalTrials":136,"cells":1325},"escitalopram",{"EARLY_PHASE1":1326,"PHASE1":1328,"PHASE2":1330,"PHASE3":1332,"PHASE4":1334,"NA":1345},{"trials":1327,"activeCount":95},[],{"trials":1329,"activeCount":95},[],{"trials":1331,"activeCount":95},[],{"trials":1333,"activeCount":95},[],{"trials":1335,"activeCount":95},[1336],{"nctId":1337,"briefTitle":1338,"status":162,"phases":1339,"primaryCompletion":1340,"completion":1341,"start":1208,"enrollment":852,"conditions":1342,"interventions":1344},"NCT01997580","Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder",[86],"2016-12","2018-12",[1343],"Major Depressive Disorder",[1324],{"trials":1346,"activeCount":95},[],{"intervention":1348,"totalTrials":136,"cells":1349},"Initial triple combination",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1367},{"trials":1351,"activeCount":95},[],{"trials":1353,"activeCount":95},[],{"trials":1355,"activeCount":95},[],{"trials":1357,"activeCount":95},[],{"trials":1359,"activeCount":95},[1360],{"nctId":1361,"briefTitle":1362,"status":105,"phases":1363,"primaryCompletion":1179,"completion":1179,"start":1316,"enrollment":199,"conditions":1364,"interventions":1365},"NCT02188186","Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients",[86],[24],[1348,1366],"Conventional treatment",{"trials":1368,"activeCount":95},[],{"intervention":1366,"totalTrials":136,"cells":1370},{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1379,"NA":1385},{"trials":1372,"activeCount":95},[],{"trials":1374,"activeCount":95},[],{"trials":1376,"activeCount":95},[],{"trials":1378,"activeCount":95},[],{"trials":1380,"activeCount":95},[1381],{"nctId":1361,"briefTitle":1362,"status":105,"phases":1382,"primaryCompletion":1179,"completion":1179,"start":1316,"enrollment":199,"conditions":1383,"interventions":1384},[86],[24],[1348,1366],{"trials":1386,"activeCount":95},[],{"intervention":1388,"totalTrials":136,"cells":1389},"Vildagliptin",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1398,"NA":1411},{"trials":1391,"activeCount":95},[],{"trials":1393,"activeCount":95},[],{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[],{"trials":1399,"activeCount":95},[1400],{"nctId":1401,"briefTitle":1402,"status":105,"phases":1403,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1409},"NCT01099137","Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin",[86],"2012-12","2013-05","2010-01",344,[21],[1388,1410],"Sulphonylurea dose-up",{"trials":1412,"activeCount":95},[],{"intervention":1410,"totalTrials":136,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1421,"PHASE4":1423,"NA":1429},{"trials":1416,"activeCount":95},[],{"trials":1418,"activeCount":95},[],{"trials":1420,"activeCount":95},[],{"trials":1422,"activeCount":95},[],{"trials":1424,"activeCount":95},[1425],{"nctId":1401,"briefTitle":1402,"status":105,"phases":1426,"primaryCompletion":1404,"completion":1405,"start":1406,"enrollment":1407,"conditions":1427,"interventions":1428},[86],[21],[1388,1410],{"trials":1430,"activeCount":95},[],{"intervention":1432,"totalTrials":136,"cells":1433},"Celecoxib",{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1440,"PHASE4":1442,"NA":1455},{"trials":1435,"activeCount":95},[],{"trials":1437,"activeCount":95},[],{"trials":1439,"activeCount":95},[],{"trials":1441,"activeCount":95},[],{"trials":1443,"activeCount":95},[1444],{"nctId":1445,"briefTitle":1446,"status":105,"phases":1447,"primaryCompletion":1180,"completion":1180,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1452},"NCT02850211","A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair",[86],"2011-09",180,[1451],"Rotator Cuff Tear",[1432,1453,1454],"Ibuprofen","Tramadol",{"trials":1456,"activeCount":95},[],{"intervention":1453,"totalTrials":136,"cells":1458},{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1467,"NA":1473},{"trials":1460,"activeCount":95},[],{"trials":1462,"activeCount":95},[],{"trials":1464,"activeCount":95},[],{"trials":1466,"activeCount":95},[],{"trials":1468,"activeCount":95},[1469],{"nctId":1445,"briefTitle":1446,"status":105,"phases":1470,"primaryCompletion":1180,"completion":1180,"start":1448,"enrollment":1449,"conditions":1471,"interventions":1472},[86],[1451],[1432,1453,1454],{"trials":1474,"activeCount":95},[],{"intervention":1454,"totalTrials":136,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1491},{"trials":1478,"activeCount":95},[],{"trials":1480,"activeCount":95},[],{"trials":1482,"activeCount":95},[],{"trials":1484,"activeCount":95},[],{"trials":1486,"activeCount":95},[1487],{"nctId":1445,"briefTitle":1446,"status":105,"phases":1488,"primaryCompletion":1180,"completion":1180,"start":1448,"enrollment":1449,"conditions":1489,"interventions":1490},[86],[1451],[1432,1453,1454],{"trials":1492,"activeCount":95},[],{"intervention":1494,"totalTrials":136,"cells":1495},"TAP block",{"EARLY_PHASE1":1496,"PHASE1":1498,"PHASE2":1500,"PHASE3":1502,"PHASE4":1504,"NA":1518},{"trials":1497,"activeCount":95},[],{"trials":1499,"activeCount":95},[],{"trials":1501,"activeCount":95},[],{"trials":1503,"activeCount":95},[],{"trials":1505,"activeCount":95},[1506],{"nctId":1507,"briefTitle":1508,"status":162,"phases":1509,"primaryCompletion":1510,"completion":1511,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1516},"NCT03805269","Transversus Abdominis Plane(TAP) Block Versus Local Anesthetic Infiltration",[86],"2024-12-28","2024-12-31","2019-03-14",94,[1515],"Pain, Postoperative",[1494,1517],"wound infiltration",{"trials":1519,"activeCount":95},[],{"intervention":1517,"totalTrials":136,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1536},{"trials":1523,"activeCount":95},[],{"trials":1525,"activeCount":95},[],{"trials":1527,"activeCount":95},[],{"trials":1529,"activeCount":95},[],{"trials":1531,"activeCount":95},[1532],{"nctId":1507,"briefTitle":1508,"status":162,"phases":1533,"primaryCompletion":1510,"completion":1511,"start":1512,"enrollment":1513,"conditions":1534,"interventions":1535},[86],[1515],[1494,1517],{"trials":1537,"activeCount":95},[],{"intervention":1539,"totalTrials":136,"cells":1540},"400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1562},{"trials":1542,"activeCount":95},[],{"trials":1544,"activeCount":95},[],{"trials":1546,"activeCount":95},[],{"trials":1548,"activeCount":95},[],{"trials":1550,"activeCount":95},[1551],{"nctId":1552,"briefTitle":1553,"status":105,"phases":1554,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1558,"conditions":1559,"interventions":1561},"NCT02031692","Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV",[86],"2017-05-26","2017-06-15","2013-12",1050,[1560],"Benign Paroxysmal Positional Vertigo",[1539],{"trials":1563,"activeCount":95},[],{"intervention":1565,"totalTrials":136,"cells":1566},"Olmesartan",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1586},{"trials":1568,"activeCount":95},[],{"trials":1570,"activeCount":95},[],{"trials":1572,"activeCount":95},[],{"trials":1574,"activeCount":95},[],{"trials":1576,"activeCount":95},[1577],{"nctId":1578,"briefTitle":1579,"status":105,"phases":1580,"primaryCompletion":1034,"completion":1581,"start":1582,"enrollment":438,"conditions":1583,"interventions":1585},"NCT05189015","Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension",[86],"2023-06-30","2021-01-01",[1584,34,304],"Angiotensin\u002FRenin\u002FAldosterone Hypertension",[1565],{"trials":1587,"activeCount":95},[],{"intervention":1589,"totalTrials":136,"cells":1590},"Modafinil",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1599,"NA":1610},{"trials":1592,"activeCount":95},[],{"trials":1594,"activeCount":95},[],{"trials":1596,"activeCount":95},[],{"trials":1598,"activeCount":95},[],{"trials":1600,"activeCount":95},[1601],{"nctId":1602,"briefTitle":1603,"status":162,"phases":1604,"primaryCompletion":1008,"completion":1008,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1609},"NCT02385656","The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study",[86],"2013-03",20,[1608],"Fatigue",[1589],{"trials":1611,"activeCount":95},[],{"intervention":1613,"totalTrials":136,"cells":1614},"Ferinject",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1635},{"trials":1616,"activeCount":95},[],{"trials":1618,"activeCount":95},[],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"trials":1624,"activeCount":95},[1625],{"nctId":1626,"briefTitle":1627,"status":162,"phases":1628,"primaryCompletion":197,"completion":1511,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1633},"NCT05429749","Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery",[86],"2020-07-30",264,[1632],"Hip Fractures",[1613,1634],"Normal saline",{"trials":1636,"activeCount":95},[],{"intervention":1638,"totalTrials":136,"cells":1639},"Aspirin 100mg",{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1662},{"trials":1641,"activeCount":95},[],{"trials":1643,"activeCount":95},[],{"trials":1645,"activeCount":95},[],{"trials":1647,"activeCount":95},[],{"trials":1649,"activeCount":95},[1650],{"nctId":1651,"briefTitle":1652,"status":105,"phases":1653,"primaryCompletion":1654,"completion":1654,"start":1655,"enrollment":1656,"conditions":1657,"interventions":1660},"NCT05257824","Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling",[86],"2025-12-02","2022-06-23",528,[1658,1659],"Aneurysm Cerebral","Endovascular Procedures",[1638,1661],"Clopidogrel 75mg",{"trials":1663,"activeCount":95},[],{"intervention":1661,"totalTrials":136,"cells":1665},{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1672,"PHASE4":1674,"NA":1680},{"trials":1667,"activeCount":95},[],{"trials":1669,"activeCount":95},[],{"trials":1671,"activeCount":95},[],{"trials":1673,"activeCount":95},[],{"trials":1675,"activeCount":95},[1676],{"nctId":1651,"briefTitle":1652,"status":105,"phases":1677,"primaryCompletion":1654,"completion":1654,"start":1655,"enrollment":1656,"conditions":1678,"interventions":1679},[86],[1658,1659],[1638,1661],{"trials":1681,"activeCount":95},[],{"intervention":1683,"totalTrials":136,"cells":1684},"3ml-Rejuvinex",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1693,"NA":1706},{"trials":1686,"activeCount":95},[],{"trials":1688,"activeCount":95},[],{"trials":1690,"activeCount":95},[],{"trials":1692,"activeCount":95},[],{"trials":1694,"activeCount":95},[1695],{"nctId":1696,"briefTitle":1697,"status":105,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1011,"conditions":1702,"interventions":1704},"NCT02492945","Bundang Rehabilitative Impact Study of the Elbow Epicondylitis",[86],"2016-09","2016-10","2015-06",[1703],"Lateral Epicondylitis",[1683,1705],"3ml-15%-dextrose solution",{"trials":1707,"activeCount":95},[],{"intervention":1705,"totalTrials":136,"cells":1709},{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1724},{"trials":1711,"activeCount":95},[],{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[],{"trials":1717,"activeCount":95},[],{"trials":1719,"activeCount":95},[1720],{"nctId":1696,"briefTitle":1697,"status":105,"phases":1721,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1011,"conditions":1722,"interventions":1723},[86],[1703],[1683,1705],{"trials":1725,"activeCount":95},[],{"intervention":1727,"totalTrials":136,"cells":1728},"CarVeDilol-SR",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1737,"NA":1751},{"trials":1730,"activeCount":95},[],{"trials":1732,"activeCount":95},[],{"trials":1734,"activeCount":95},[],{"trials":1736,"activeCount":95},[],{"trials":1738,"activeCount":95},[1739],{"nctId":1740,"briefTitle":1741,"status":162,"phases":1742,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":1746,"conditions":1747,"interventions":1749},"NCT03209180","Immediate Release Versus Slow Release Carvedilol in Heart Failure",[86],"2018-06-25","2018-12-31","2016-10-27",320,[1748],"Heart Failure With Reduced Ejection Fraction",[1727,1750],"Carvedilol IR",{"trials":1752,"activeCount":95},[],{"intervention":1750,"totalTrials":136,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1761,"PHASE4":1763,"NA":1769},{"trials":1756,"activeCount":95},[],{"trials":1758,"activeCount":95},[],{"trials":1760,"activeCount":95},[],{"trials":1762,"activeCount":95},[],{"trials":1764,"activeCount":95},[1765],{"nctId":1740,"briefTitle":1741,"status":162,"phases":1766,"primaryCompletion":1743,"completion":1744,"start":1745,"enrollment":1746,"conditions":1767,"interventions":1768},[86],[1748],[1727,1750],{"trials":1770,"activeCount":95},[],{"intervention":1184,"totalTrials":136,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1787},{"trials":1774,"activeCount":95},[],{"trials":1776,"activeCount":95},[],{"trials":1778,"activeCount":95},[],{"trials":1780,"activeCount":95},[],{"trials":1782,"activeCount":95},[1783],{"nctId":1175,"briefTitle":1176,"status":105,"phases":1784,"primaryCompletion":1178,"completion":1179,"start":1180,"enrollment":1181,"conditions":1785,"interventions":1786},[86],[21],[234,1184],{"trials":1788,"activeCount":95},[],{"intervention":1790,"totalTrials":136,"cells":1791},"Tirofiban",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1800,"NA":1811},{"trials":1793,"activeCount":95},[],{"trials":1795,"activeCount":95},[],{"trials":1797,"activeCount":95},[],{"trials":1799,"activeCount":95},[],{"trials":1801,"activeCount":95},[1802],{"nctId":1803,"briefTitle":1804,"status":105,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1050,"conditions":1808,"interventions":1810},"NCT03114995","Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients",[86],"2015-10-01","2012-02-01",[1809],"Non-ST Elevation Myocardial Infarction",[1790],{"trials":1812,"activeCount":95},[],{"intervention":1814,"totalTrials":136,"cells":1815},"Fluorescein Sodium",{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1822,"PHASE4":1824,"NA":1836},{"trials":1817,"activeCount":95},[],{"trials":1819,"activeCount":95},[],{"trials":1821,"activeCount":95},[],{"trials":1823,"activeCount":95},[],{"trials":1825,"activeCount":95},[1826],{"nctId":1827,"briefTitle":1828,"status":105,"phases":1829,"primaryCompletion":1830,"completion":1830,"start":1831,"enrollment":1832,"conditions":1833,"interventions":1835},"NCT05664555","Dose Optimization for Safe and Efficient Fluorescein Angiography (DOSE Study)",[86],"2024-03-31","2023-02-01",144,[1834],"Retinal Disease",[1814],{"trials":1837,"activeCount":95},[],{"intervention":1839,"totalTrials":136,"cells":1840},"Quetiapine",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1847,"PHASE4":1849,"NA":1861},{"trials":1842,"activeCount":95},[],{"trials":1844,"activeCount":95},[],{"trials":1846,"activeCount":95},[],{"trials":1848,"activeCount":95},[],{"trials":1850,"activeCount":95},[1851],{"nctId":1852,"briefTitle":1853,"status":162,"phases":1854,"primaryCompletion":1855,"completion":1856,"start":1857,"enrollment":1272,"conditions":1858,"interventions":1860},"NCT01213121","Neurophysiologic Changes in Patients With Bipolar Depression",[86],"2014-10","2015-10","2010-09",[1859],"Bipolar Depression",[1839],{"trials":1862,"activeCount":95},[],{"intervention":1864,"totalTrials":136,"cells":1865},"Ranibizumab",{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1872,"PHASE4":1874,"NA":1888},{"trials":1867,"activeCount":95},[],{"trials":1869,"activeCount":95},[],{"trials":1871,"activeCount":95},[],{"trials":1873,"activeCount":95},[],{"trials":1875,"activeCount":95},[1876],{"nctId":1877,"briefTitle":1878,"status":1879,"phases":1880,"primaryCompletion":1881,"completion":1881,"start":1882,"enrollment":1883,"conditions":1884,"interventions":1887},"NCT01795209","Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision","TERMINATED",[86],"2017-12","2013-01",19,[1885,1886],"Branch Retinal Vein Occlusion","Macular Edema",[1864],{"trials":1889,"activeCount":95},[],{"intervention":1054,"totalTrials":136,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1906},{"trials":1893,"activeCount":95},[],{"trials":1895,"activeCount":95},[],{"trials":1897,"activeCount":95},[],{"trials":1899,"activeCount":95},[],{"trials":1901,"activeCount":95},[1902],{"nctId":1044,"briefTitle":1045,"status":105,"phases":1903,"primaryCompletion":1047,"completion":1048,"start":1049,"enrollment":1050,"conditions":1904,"interventions":1905},[86],[21],[1053,1054],{"trials":1907,"activeCount":95},[],{"intervention":1909,"totalTrials":136,"cells":1910},"Forsteo",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1919,"NA":1932},{"trials":1912,"activeCount":95},[],{"trials":1914,"activeCount":95},[],{"trials":1916,"activeCount":95},[],{"trials":1918,"activeCount":95},[],{"trials":1920,"activeCount":95},[1921],{"nctId":1922,"briefTitle":1923,"status":162,"phases":1924,"primaryCompletion":1744,"completion":1925,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1930},"NCT04241211","Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled Trial",[86],"2020-12-31","2014-01-01",64,[1929],"Spine Deformity",[1909,1931],"Denosumab Prefilled Syringe [Prolia]",{"trials":1933,"activeCount":95},[],{"intervention":1931,"totalTrials":136,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1950},{"trials":1937,"activeCount":95},[],{"trials":1939,"activeCount":95},[],{"trials":1941,"activeCount":95},[],{"trials":1943,"activeCount":95},[],{"trials":1945,"activeCount":95},[1946],{"nctId":1922,"briefTitle":1923,"status":162,"phases":1947,"primaryCompletion":1744,"completion":1925,"start":1926,"enrollment":1927,"conditions":1948,"interventions":1949},[86],[1929],[1909,1931],{"trials":1951,"activeCount":95},[],{"intervention":205,"totalTrials":136,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1960,"PHASE4":1962,"NA":1968},{"trials":1955,"activeCount":95},[],{"trials":1957,"activeCount":95},[],{"trials":1959,"activeCount":95},[],{"trials":1961,"activeCount":95},[],{"trials":1963,"activeCount":95},[1964],{"nctId":194,"briefTitle":195,"status":162,"phases":1965,"primaryCompletion":197,"completion":197,"start":198,"enrollment":199,"conditions":1966,"interventions":1967},[86],[201,202],[204,205],{"trials":1969,"activeCount":95},[],{"intervention":1971,"totalTrials":136,"cells":1972},"Abciximab",{"EARLY_PHASE1":1973,"PHASE1":1975,"PHASE2":1977,"PHASE3":1979,"PHASE4":1981,"NA":1991},{"trials":1974,"activeCount":95},[],{"trials":1976,"activeCount":95},[],{"trials":1978,"activeCount":95},[],{"trials":1980,"activeCount":95},[],{"trials":1982,"activeCount":95},[1983],{"nctId":1984,"briefTitle":1985,"status":105,"phases":1986,"primaryCompletion":1448,"completion":1987,"start":1857,"enrollment":464,"conditions":1988,"interventions":1989},"NCT01475552","Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus",[86],"2011-10",[201],[1971,1990],"control",{"trials":1992,"activeCount":95},[],{"intervention":1990,"totalTrials":136,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2009},{"trials":1996,"activeCount":95},[],{"trials":1998,"activeCount":95},[],{"trials":2000,"activeCount":95},[],{"trials":2002,"activeCount":95},[],{"trials":2004,"activeCount":95},[2005],{"nctId":1984,"briefTitle":1985,"status":105,"phases":2006,"primaryCompletion":1448,"completion":1987,"start":1857,"enrollment":464,"conditions":2007,"interventions":2008},[86],[201],[1971,1990],{"trials":2010,"activeCount":95},[],{"intervention":1137,"totalTrials":136,"cells":2012},{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2021,"NA":2027},{"trials":2014,"activeCount":95},[],{"trials":2016,"activeCount":95},[],{"trials":2018,"activeCount":95},[],{"trials":2020,"activeCount":95},[],{"trials":2022,"activeCount":95},[2023],{"nctId":1129,"briefTitle":1130,"status":162,"phases":2024,"primaryCompletion":1132,"completion":197,"start":1133,"enrollment":438,"conditions":2025,"interventions":2026},[86],[1135],[1103,1137],{"trials":2028,"activeCount":95},[],{"intervention":235,"totalTrials":136,"cells":2030},{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2037,"PHASE4":2039,"NA":2045},{"trials":2032,"activeCount":95},[],{"trials":2034,"activeCount":95},[],{"trials":2036,"activeCount":95},[],{"trials":2038,"activeCount":95},[],{"trials":2040,"activeCount":95},[2041],{"nctId":225,"briefTitle":226,"status":105,"phases":2042,"primaryCompletion":228,"completion":164,"start":229,"enrollment":230,"conditions":2043,"interventions":2044},[86],[24],[233,234,169,235,192],{"trials":2046,"activeCount":95},[],{"intervention":2048,"totalTrials":136,"cells":2049},"S-amlodipine 2.5mg + Chlorthalidone 25mg",{"EARLY_PHASE1":2050,"PHASE1":2052,"PHASE2":2054,"PHASE3":2056,"PHASE4":2058,"NA":2070},{"trials":2051,"activeCount":95},[],{"trials":2053,"activeCount":95},[],{"trials":2055,"activeCount":95},[],{"trials":2057,"activeCount":95},[],{"trials":2059,"activeCount":95},[2060],{"nctId":2061,"briefTitle":2062,"status":162,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":1037,"conditions":2066,"interventions":2068},"NCT03226340","S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension",[86],"2018-03-31","2015-12-02",[2067],"Essential Hypertension",[2048,2069],"S-amlodipine 2.5mg + Telmisartan 40mg",{"trials":2071,"activeCount":95},[],{"intervention":2069,"totalTrials":136,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2082,"NA":2088},{"trials":2075,"activeCount":95},[],{"trials":2077,"activeCount":95},[],{"trials":2079,"activeCount":95},[],{"trials":2081,"activeCount":95},[],{"trials":2083,"activeCount":95},[2084],{"nctId":2061,"briefTitle":2062,"status":162,"phases":2085,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":1037,"conditions":2086,"interventions":2087},[86],[2067],[2048,2069],{"trials":2089,"activeCount":95},[],{"intervention":2091,"totalTrials":136,"cells":2092},"Carvedilol",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2101,"NA":2115},{"trials":2094,"activeCount":95},[],{"trials":2096,"activeCount":95},[],{"trials":2098,"activeCount":95},[],{"trials":2100,"activeCount":95},[],{"trials":2102,"activeCount":95},[2103],{"nctId":2104,"briefTitle":2105,"status":105,"phases":2106,"primaryCompletion":2107,"completion":2107,"start":2108,"enrollment":2109,"conditions":2110,"interventions":2114},"NCT05553314","Carvedilol in HF With Preserved EF",[86],"2026-01-08","2021-11-17",63,[2111,2112,2113],"Heart Failure With Preserved Ejection Fraction","Beta Blocker","Myocardial Strain",[2091],{"trials":2116,"activeCount":95},[],{"intervention":2118,"totalTrials":136,"cells":2119},"Rosuvastatin",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2138},{"trials":2121,"activeCount":95},[],{"trials":2123,"activeCount":95},[],{"trials":2125,"activeCount":95},[],{"trials":2127,"activeCount":95},[],{"trials":2129,"activeCount":95},[2130],{"nctId":2131,"briefTitle":2132,"status":105,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":1855,"enrollment":131,"conditions":2136,"interventions":2137},"NCT02185963","Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes",[86],"2015-12","2016-05",[21],[2118],{"trials":2139,"activeCount":95},[],{"intervention":2141,"totalTrials":136,"cells":2142},"human recombinant erythropoietin",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2151,"NA":2163},{"trials":2144,"activeCount":95},[],{"trials":2146,"activeCount":95},[],{"trials":2148,"activeCount":95},[],{"trials":2150,"activeCount":95},[],{"trials":2152,"activeCount":95},[2153],{"nctId":2154,"briefTitle":2155,"status":105,"phases":2156,"primaryCompletion":2157,"completion":2157,"start":2158,"enrollment":2159,"conditions":2160,"interventions":2162},"NCT00882466","The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction",[86],"2009-02","2008-05",58,[2161],"Acute Myocardial Infarction",[2141],{"trials":2164,"activeCount":95},[],{"intervention":2166,"totalTrials":136,"cells":2167},"Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin",{"EARLY_PHASE1":2168,"PHASE1":2170,"PHASE2":2172,"PHASE3":2174,"PHASE4":2176,"NA":2189},{"trials":2169,"activeCount":95},[],{"trials":2171,"activeCount":95},[],{"trials":2173,"activeCount":95},[],{"trials":2175,"activeCount":95},[],{"trials":2177,"activeCount":95},[2178],{"nctId":2179,"briefTitle":2180,"status":105,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":2184,"enrollment":2185,"conditions":2186,"interventions":2188},"NCT04080310","Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin",[86],"2019-06-15","2019-09-17","2018-03-15",270,[2187],"Cardiovascular Diseases",[2166],{"trials":2190,"activeCount":95},[],{"intervention":2192,"totalTrials":136,"cells":2193},"Dapagliflozin 10mg Tab",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2202,"NA":2216},{"trials":2195,"activeCount":95},[],{"trials":2197,"activeCount":95},[],{"trials":2199,"activeCount":95},[],{"trials":2201,"activeCount":95},[],{"trials":2203,"activeCount":95},[2204],{"nctId":2205,"briefTitle":2206,"status":162,"phases":2207,"primaryCompletion":2208,"completion":197,"start":2209,"enrollment":2210,"conditions":2211,"interventions":2213},"NCT05915949","Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety",[86],"2023-10-30","2022-01-01",99,[2212],"Diabetes Type 2",[2192,2214,2215],"Lobeglitazone 0.5 mg","Dapagliflozin + Lobeglitazone",{"trials":2217,"activeCount":95},[],{"intervention":2214,"totalTrials":136,"cells":2219},{"EARLY_PHASE1":2220,"PHASE1":2222,"PHASE2":2224,"PHASE3":2226,"PHASE4":2228,"NA":2234},{"trials":2221,"activeCount":95},[],{"trials":2223,"activeCount":95},[],{"trials":2225,"activeCount":95},[],{"trials":2227,"activeCount":95},[],{"trials":2229,"activeCount":95},[2230],{"nctId":2205,"briefTitle":2206,"status":162,"phases":2231,"primaryCompletion":2208,"completion":197,"start":2209,"enrollment":2210,"conditions":2232,"interventions":2233},[86],[2212],[2192,2214,2215],{"trials":2235,"activeCount":95},[],{"intervention":2215,"totalTrials":136,"cells":2237},{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2242,"PHASE3":2244,"PHASE4":2246,"NA":2252},{"trials":2239,"activeCount":95},[],{"trials":2241,"activeCount":95},[],{"trials":2243,"activeCount":95},[],{"trials":2245,"activeCount":95},[],{"trials":2247,"activeCount":95},[2248],{"nctId":2205,"briefTitle":2206,"status":162,"phases":2249,"primaryCompletion":2208,"completion":197,"start":2209,"enrollment":2210,"conditions":2250,"interventions":2251},[86],[2212],[2192,2214,2215],{"trials":2253,"activeCount":95},[],{"intervention":2255,"totalTrials":136,"cells":2256},"Pitavastatin",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2265,"NA":2280},{"trials":2258,"activeCount":95},[],{"trials":2260,"activeCount":95},[],{"trials":2262,"activeCount":95},[],{"trials":2264,"activeCount":95},[],{"trials":2266,"activeCount":95},[2267],{"nctId":2268,"briefTitle":2269,"status":105,"phases":2270,"primaryCompletion":2271,"completion":2272,"start":2273,"enrollment":2274,"conditions":2275,"interventions":2279},"NCT06359353","Effect of Pitavastatin on Bone",[86],"2022-02-10","2023-12-19","2019-04-08",70,[2276,2277,2278],"Osteoporosis, Osteopenia","Hypercholesterolemia","Menopausal Osteoporosis",[2255],{"trials":2281,"activeCount":95},[],{"intervention":2283,"totalTrials":136,"cells":2284},"deep block",{"EARLY_PHASE1":2285,"PHASE1":2287,"PHASE2":2289,"PHASE3":2291,"PHASE4":2293,"NA":2304},{"trials":2286,"activeCount":95},[],{"trials":2288,"activeCount":95},[],{"trials":2290,"activeCount":95},[],{"trials":2292,"activeCount":95},[],{"trials":2294,"activeCount":95},[2295],{"nctId":2296,"briefTitle":2297,"status":105,"phases":2298,"primaryCompletion":2299,"completion":2300,"start":2301,"enrollment":1080,"conditions":2302,"interventions":2303},"NCT02100280","The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy",[86],"2017-06-14","2017-06-16","2014-06-29",[27],[2283],{"trials":2305,"activeCount":95},[],{"intervention":2307,"totalTrials":136,"cells":2308},"contrast agent",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2329},{"trials":2310,"activeCount":95},[],{"trials":2312,"activeCount":95},[],{"trials":2314,"activeCount":95},[],{"trials":2316,"activeCount":95},[],{"trials":2318,"activeCount":95},[2319],{"nctId":2320,"briefTitle":2321,"status":105,"phases":2322,"primaryCompletion":1209,"completion":2323,"start":2157,"enrollment":2324,"conditions":2325,"interventions":2328},"NCT00823628","Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus Iopromide",[86],"2010-06",420,[2326,2327],"Chronic Renal Insufficiency","Coronary Angiography",[2307,2307],{"trials":2330,"activeCount":95},[],{"intervention":2332,"totalTrials":136,"cells":2333},"sitagliptin, metformin",{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2338,"PHASE3":2340,"PHASE4":2342,"NA":2353},{"trials":2335,"activeCount":95},[],{"trials":2337,"activeCount":95},[],{"trials":2339,"activeCount":95},[],{"trials":2341,"activeCount":95},[],{"trials":2343,"activeCount":95},[2344],{"nctId":2345,"briefTitle":2346,"status":105,"phases":2347,"primaryCompletion":2323,"completion":2348,"start":2349,"enrollment":2350,"conditions":2351,"interventions":2352},"NCT00969566","Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination",[86],"2011-07","2009-01",150,[21],[2332],{"trials":2354,"activeCount":95},[],{"intervention":2356,"totalTrials":136,"cells":2357},"Empagliflozin",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2364,"PHASE4":2366,"NA":2380},{"trials":2359,"activeCount":95},[],{"trials":2361,"activeCount":95},[],{"trials":2363,"activeCount":95},[],{"trials":2365,"activeCount":95},[],{"trials":2367,"activeCount":95},[2368],{"nctId":2369,"briefTitle":2370,"status":162,"phases":2371,"primaryCompletion":2372,"completion":186,"start":2373,"enrollment":2374,"conditions":2375,"interventions":2377},"NCT05140694","Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D",[86],"2024-06-30","2023-12-01",135,[2376,24],"Metabolic-associated Fatty Liver Disease",[2356,2378,2379],"Dulaglutide","Empagliflozin and Dulaglutide",{"trials":2381,"activeCount":95},[],{"intervention":2378,"totalTrials":136,"cells":2383},{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2390,"PHASE4":2392,"NA":2398},{"trials":2385,"activeCount":95},[],{"trials":2387,"activeCount":95},[],{"trials":2389,"activeCount":95},[],{"trials":2391,"activeCount":95},[],{"trials":2393,"activeCount":95},[2394],{"nctId":2369,"briefTitle":2370,"status":162,"phases":2395,"primaryCompletion":2372,"completion":186,"start":2373,"enrollment":2374,"conditions":2396,"interventions":2397},[86],[2376,24],[2356,2378,2379],{"trials":2399,"activeCount":95},[],{"intervention":2379,"totalTrials":136,"cells":2401},{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2416},{"trials":2403,"activeCount":95},[],{"trials":2405,"activeCount":95},[],{"trials":2407,"activeCount":95},[],{"trials":2409,"activeCount":95},[],{"trials":2411,"activeCount":95},[2412],{"nctId":2369,"briefTitle":2370,"status":162,"phases":2413,"primaryCompletion":2372,"completion":186,"start":2373,"enrollment":2374,"conditions":2414,"interventions":2415},[86],[2376,24],[2356,2378,2379],{"trials":2417,"activeCount":95},[],{"intervention":2419,"totalTrials":136,"cells":2420},"zoledronic acid",{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2425,"PHASE3":2427,"PHASE4":2439,"NA":2441},{"trials":2422,"activeCount":95},[],{"trials":2424,"activeCount":95},[],{"trials":2426,"activeCount":95},[],{"trials":2428,"activeCount":95},[2429],{"nctId":2430,"briefTitle":2431,"status":105,"phases":2432,"primaryCompletion":2433,"completion":2433,"start":2434,"enrollment":2435,"conditions":2436,"interventions":2438},"NCT00939900","Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head",[85],"2012-06","2009-07",110,[2437],"Avascular Necrosis of Femoral Head",[2419],{"trials":2440,"activeCount":95},[],{"trials":2442,"activeCount":95},[],{"intervention":1040,"totalTrials":136,"cells":2444},{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2457,"NA":2459},{"trials":2446,"activeCount":95},[],{"trials":2448,"activeCount":95},[],{"trials":2450,"activeCount":95},[],{"trials":2452,"activeCount":95},[2453],{"nctId":1031,"briefTitle":1032,"status":105,"phases":2454,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":1037,"conditions":2455,"interventions":2456},[85],[133],[1040,233],{"trials":2458,"activeCount":95},[],{"trials":2460,"activeCount":95},[],{"intervention":1125,"totalTrials":136,"cells":2462},{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2475,"NA":2477},{"trials":2464,"activeCount":95},[],{"trials":2466,"activeCount":95},[],{"trials":2468,"activeCount":95},[],{"trials":2470,"activeCount":95},[2471],{"nctId":1114,"briefTitle":1115,"status":162,"phases":2472,"primaryCompletion":1117,"completion":1118,"start":1119,"enrollment":1120,"conditions":2473,"interventions":2474},[84,85],[1122,1123],[1103,1125],{"trials":2476,"activeCount":95},[],{"trials":2478,"activeCount":95},[],{"intervention":2480,"totalTrials":136,"cells":2481},"Choline alfoscerate",{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2486,"PHASE3":2488,"PHASE4":2500,"NA":2502},{"trials":2483,"activeCount":95},[],{"trials":2485,"activeCount":95},[],{"trials":2487,"activeCount":95},[],{"trials":2489,"activeCount":95},[2490],{"nctId":2491,"briefTitle":2492,"status":105,"phases":2493,"primaryCompletion":2494,"completion":2495,"start":2496,"enrollment":2497,"conditions":2498,"interventions":2499},"NCT03249259","The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes",[85],"2019-06-30","2019-09-30","2016-03-10",36,[304],[2480],{"trials":2501,"activeCount":95},[],{"trials":2503,"activeCount":95},[],{"intervention":2505,"totalTrials":136,"cells":2506},"Probiotic Combination Cap\u002FTab",{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2527,"NA":2529},{"trials":2508,"activeCount":95},[],{"trials":2510,"activeCount":95},[],{"trials":2512,"activeCount":95},[],{"trials":2514,"activeCount":95},[2515],{"nctId":2516,"briefTitle":2517,"status":105,"phases":2518,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":2522,"conditions":2523,"interventions":2525},"NCT05604989","Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration",[85],"2024-08-31","2024-11-30","2023-01-01",45,[2524],"Neovascular Age-related Macular Degeneration",[2505,2526],"intravitreal Anti-VEGF",{"trials":2528,"activeCount":95},[],{"trials":2530,"activeCount":95},[],{"intervention":2532,"totalTrials":136,"cells":2533},"Erythropoietin-Beta",{"EARLY_PHASE1":2534,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2553,"NA":2555},{"trials":2535,"activeCount":95},[],{"trials":2537,"activeCount":95},[],{"trials":2539,"activeCount":95},[],{"trials":2541,"activeCount":95},[2542],{"nctId":2543,"briefTitle":2544,"status":105,"phases":2545,"primaryCompletion":2546,"completion":2157,"start":2547,"enrollment":2548,"conditions":2549,"interventions":2551},"NCT00654992","Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery",[84,85],"2008-02","2006-09",71,[2550],"Kidney Failure, Acute",[2532,2552],"Normal Saline",{"trials":2554,"activeCount":95},[],{"trials":2556,"activeCount":95},[],{"intervention":2558,"totalTrials":136,"cells":2559},"darbepoetin-α",{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2566,"PHASE4":2577,"NA":2579},{"trials":2561,"activeCount":95},[],{"trials":2563,"activeCount":95},[],{"trials":2565,"activeCount":95},[],{"trials":2567,"activeCount":95},[2568],{"nctId":2569,"briefTitle":2570,"status":1879,"phases":2571,"primaryCompletion":2134,"completion":2134,"start":2572,"enrollment":438,"conditions":2573,"interventions":2575},"NCT01197235","Effect of Darbepoetin in Contrast-induced Nephropathy",[84,85],"2009-05",[2574],"Acute Kidney Injury",[2558,2576],"isotonic saline",{"trials":2578,"activeCount":95},[],{"trials":2580,"activeCount":95},[],{"intervention":2576,"totalTrials":136,"cells":2582},{"EARLY_PHASE1":2583,"PHASE1":2585,"PHASE2":2587,"PHASE3":2589,"PHASE4":2595,"NA":2597},{"trials":2584,"activeCount":95},[],{"trials":2586,"activeCount":95},[],{"trials":2588,"activeCount":95},[],{"trials":2590,"activeCount":95},[2591],{"nctId":2569,"briefTitle":2570,"status":1879,"phases":2592,"primaryCompletion":2134,"completion":2134,"start":2572,"enrollment":438,"conditions":2593,"interventions":2594},[84,85],[2574],[2558,2576],{"trials":2596,"activeCount":95},[],{"trials":2598,"activeCount":95},[],{"intervention":2600,"totalTrials":136,"cells":2601},"BST-104",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2608,"PHASE4":2622,"NA":2624},{"trials":2603,"activeCount":95},[],{"trials":2605,"activeCount":95},[],{"trials":2607,"activeCount":95},[],{"trials":2609,"activeCount":95},[2610],{"nctId":2611,"briefTitle":2612,"status":105,"phases":2613,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":2617,"conditions":2618,"interventions":2621},"NCT04008901","The Efficacy and Safety of \"BST104\" (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects",[85],"2018-07-02","2018-11-08","2017-02-13",92,[2619,2620],"Functional Dyspepsia","Irritable Bowel Syndrome",[2600],{"trials":2623,"activeCount":95},[],{"trials":2625,"activeCount":95},[],{"intervention":2627,"totalTrials":141,"cells":2628},"Paclitaxel",{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2630,"activeCount":95},[],{"trials":2632,"activeCount":95},[],{"trials":2634,"activeCount":95},[2635,2650],{"nctId":2636,"briefTitle":2637,"status":105,"phases":2638,"primaryCompletion":2639,"completion":2640,"start":2641,"enrollment":2642,"conditions":2643,"interventions":2648},"NCT03618758","Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6",[83,84],"2023-08-31","2023-12-02","2018-12-24",35,[2644,2645,2646,2647],"Gastric Cancer Stage IV","Peritoneal Carcinomatosis","Intraperitoneal Paclitaxel","mFOLFOX6",[2627,2649],"mFOLFOX6 regimen",{"nctId":2651,"briefTitle":2652,"status":162,"phases":2653,"primaryCompletion":2654,"completion":2655,"start":2656,"enrollment":2657,"conditions":2658,"interventions":2660},"NCT04526470","Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer",[83,84],"2023-06","2024-12","2020-09-01",55,[674,2659],"Stomach Cancer",[2661,2627],"Alpelisib",{"trials":2663,"activeCount":95},[],{"trials":2665,"activeCount":95},[],{"trials":2667,"activeCount":95},[],{"intervention":2669,"totalTrials":136,"cells":2670},"Theragene arm",{"EARLY_PHASE1":2671,"PHASE1":2673,"PHASE2":2675,"PHASE3":2685,"PHASE4":2687,"NA":2689},{"trials":2672,"activeCount":95},[],{"trials":2674,"activeCount":95},[],{"trials":2676,"activeCount":95},[2677],{"nctId":2678,"briefTitle":2679,"status":162,"phases":2680,"primaryCompletion":2681,"completion":156,"start":631,"enrollment":541,"conditions":2682,"interventions":2684},"NCT04739046","An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy",[84],"2022-08-01",[2683],"Pancreas Cancer",[2669],{"trials":2686,"activeCount":95},[],{"trials":2688,"activeCount":95},[],{"trials":2690,"activeCount":95},[],{"intervention":2692,"totalTrials":136,"cells":2693},"Oxaliplatin,5FU, leucovorin",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2695,"activeCount":95},[],{"trials":2697,"activeCount":95},[],{"trials":2699,"activeCount":95},[2700],{"nctId":2701,"briefTitle":2702,"status":105,"phases":2703,"primaryCompletion":2704,"completion":2705,"start":2706,"enrollment":120,"conditions":2707,"interventions":2708},"NCT03464968","mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line",[84],"2020-02-10","2020-07-25","2015-07-29",[466],[2692,2709],"irinotecan,5FU, leucovorin",{"trials":2711,"activeCount":95},[],{"trials":2713,"activeCount":95},[],{"trials":2715,"activeCount":95},[],{"intervention":2709,"totalTrials":136,"cells":2717},{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2728,"PHASE4":2730,"NA":2732},{"trials":2719,"activeCount":95},[],{"trials":2721,"activeCount":95},[],{"trials":2723,"activeCount":95},[2724],{"nctId":2701,"briefTitle":2702,"status":105,"phases":2725,"primaryCompletion":2704,"completion":2705,"start":2706,"enrollment":120,"conditions":2726,"interventions":2727},[84],[466],[2692,2709],{"trials":2729,"activeCount":95},[],{"trials":2731,"activeCount":95},[],{"trials":2733,"activeCount":95},[],{"intervention":2735,"totalTrials":136,"cells":2736},"Gemcitabine and UFTE chemotherapy",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2755,"PHASE4":2757,"NA":2759},{"trials":2738,"activeCount":95},[],{"trials":2740,"activeCount":95},[],{"trials":2742,"activeCount":95},[2743],{"nctId":2744,"briefTitle":2745,"status":105,"phases":2746,"primaryCompletion":2747,"start":2748,"enrollment":2749,"conditions":2750,"interventions":2754},"NCT01409005","Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer",[84],"2013-02","2011-06",41,[2751,2752,2753],"Metastatic or Recurrent Colorectal Cancer","Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan","Salvage Chemotherapy",[2735],{"trials":2756,"activeCount":95},[],{"trials":2758,"activeCount":95},[],{"trials":2760,"activeCount":95},[],{"intervention":2762,"totalTrials":136,"cells":2763},"Darbepoetin alfa",{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2768,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2765,"activeCount":95},[],{"trials":2767,"activeCount":95},[],{"trials":2769,"activeCount":95},[2770],{"nctId":2771,"briefTitle":2772,"status":105,"phases":2773,"primaryCompletion":2774,"completion":2747,"start":2775,"enrollment":438,"conditions":2776,"interventions":2778},"NCT01538771","Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling",[84],"2012-09","2009-11",[2777],"Myocardial Infarction",[2762,2779],"Control Saline",{"trials":2781,"activeCount":95},[],{"trials":2783,"activeCount":95},[],{"trials":2785,"activeCount":95},[],{"intervention":2779,"totalTrials":136,"cells":2787},{"EARLY_PHASE1":2788,"PHASE1":2790,"PHASE2":2792,"PHASE3":2798,"PHASE4":2800,"NA":2802},{"trials":2789,"activeCount":95},[],{"trials":2791,"activeCount":95},[],{"trials":2793,"activeCount":95},[2794],{"nctId":2771,"briefTitle":2772,"status":105,"phases":2795,"primaryCompletion":2774,"completion":2747,"start":2775,"enrollment":438,"conditions":2796,"interventions":2797},[84],[2777],[2762,2779],{"trials":2799,"activeCount":95},[],{"trials":2801,"activeCount":95},[],{"trials":2803,"activeCount":95},[],{"intervention":2805,"totalTrials":136,"cells":2806},"AZD8186 in combination with paclitaxel",{"EARLY_PHASE1":2807,"PHASE1":2809,"PHASE2":2811,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2808,"activeCount":95},[],{"trials":2810,"activeCount":95},[],{"trials":2812,"activeCount":95},[2813],{"nctId":2814,"briefTitle":2815,"status":162,"phases":2816,"primaryCompletion":164,"completion":2817,"start":2818,"enrollment":2819,"conditions":2820,"interventions":2821},"NCT04001569","AZD8186 and Paclitaxel in Advanced Gastric Cancer",[83,84],"2022-12-31","2019-05-14",49,[674,2659],[2805],{"trials":2823,"activeCount":95},[],{"trials":2825,"activeCount":95},[],{"trials":2827,"activeCount":95},[],{"intervention":2649,"totalTrials":136,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2831,"activeCount":95},[],{"trials":2833,"activeCount":95},[],{"trials":2835,"activeCount":95},[2836],{"nctId":2636,"briefTitle":2637,"status":105,"phases":2837,"primaryCompletion":2639,"completion":2640,"start":2641,"enrollment":2642,"conditions":2838,"interventions":2839},[83,84],[2644,2645,2646,2647],[2627,2649],{"trials":2841,"activeCount":95},[],{"trials":2843,"activeCount":95},[],{"trials":2845,"activeCount":95},[],{"intervention":2847,"totalTrials":136,"cells":2848},"Pharmacological intensification based on olmesartan",{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2850,"activeCount":95},[],{"trials":2852,"activeCount":95},[],{"trials":2854,"activeCount":95},[2855],{"nctId":2856,"briefTitle":2857,"status":105,"phases":2858,"primaryCompletion":2859,"completion":2859,"start":2860,"enrollment":2861,"conditions":2862,"interventions":2864},"NCT03024476","Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance",[84],"2017-12-07","2016-09-01",67,[2863,34],"Ischemic Stroke",[2847],{"trials":2866,"activeCount":95},[],{"trials":2868,"activeCount":95},[],{"trials":2870,"activeCount":95},[],{"intervention":2661,"totalTrials":136,"cells":2872},{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2874,"activeCount":95},[],{"trials":2876,"activeCount":95},[],{"trials":2878,"activeCount":95},[2879],{"nctId":2651,"briefTitle":2652,"status":162,"phases":2880,"primaryCompletion":2654,"completion":2655,"start":2656,"enrollment":2657,"conditions":2881,"interventions":2882},[83,84],[674,2659],[2661,2627],{"trials":2884,"activeCount":95},[],{"trials":2886,"activeCount":95},[],{"trials":2888,"activeCount":95},[],{"intervention":2890,"totalTrials":136,"cells":2891},"Roflumilast",{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2907,"PHASE4":2909,"NA":2911},{"trials":2893,"activeCount":95},[],{"trials":2895,"activeCount":95},[],{"trials":2897,"activeCount":95},[2898],{"nctId":2899,"briefTitle":2900,"status":162,"phases":2901,"primaryCompletion":1404,"completion":1882,"start":2902,"enrollment":2903,"conditions":2904,"interventions":2906},"NCT01580748","Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients",[84],"2012-05",25,[2905],"Symptomatic Bronchiectasis",[2890],{"trials":2908,"activeCount":95},[],{"trials":2910,"activeCount":95},[],{"trials":2912,"activeCount":95},[],{"intervention":535,"totalTrials":136,"cells":2914},{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2923,"PHASE3":2925,"PHASE4":2927,"NA":2929},{"trials":2916,"activeCount":95},[],{"trials":2918,"activeCount":95},[2919],{"nctId":525,"briefTitle":526,"status":162,"phases":2920,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":2921,"interventions":2922},[83],[533],[535,518],{"trials":2924,"activeCount":95},[],{"trials":2926,"activeCount":95},[],{"trials":2928,"activeCount":95},[],{"trials":2930,"activeCount":95},[],{"intervention":1634,"totalTrials":541,"cells":2932},{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2939,"PHASE4":2945,"NA":2961},{"trials":2934,"activeCount":95},[],{"trials":2936,"activeCount":95},[],{"trials":2938,"activeCount":95},[],{"trials":2940,"activeCount":95},[2941],{"nctId":2543,"briefTitle":2544,"status":105,"phases":2942,"primaryCompletion":2546,"completion":2157,"start":2547,"enrollment":2548,"conditions":2943,"interventions":2944},[84,85],[2550],[2532,2552],{"trials":2946,"activeCount":95},[2947,2951],{"nctId":1626,"briefTitle":1627,"status":162,"phases":2948,"primaryCompletion":197,"completion":1511,"start":1629,"enrollment":1630,"conditions":2949,"interventions":2950},[86],[1632],[1613,1634],{"nctId":2952,"briefTitle":2953,"status":105,"phases":2954,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":2617,"conditions":2957,"interventions":2959},"NCT03208452","The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation",[86],"2018-12-19","2017-03-19",[2958],"Agitation,Psychomotor",[2960,1634],"Magnesium Sulfate",{"trials":2962,"activeCount":95},[2963,2978,2988,2997,3010,3019,3026,3038,3048],{"nctId":2964,"briefTitle":2965,"status":105,"phases":2966,"primaryCompletion":2967,"completion":2967,"start":1219,"enrollment":2968,"conditions":2969,"interventions":2975},"NCT01153256","Intubating Condition After Magnesium Pre-treatment",[87],"2011-03",168,[2970,2971,2972,2973,2974],"Easy of Laryngoscopy Manipulation","Vocal Cord Position or Movement","Patient Reaction to Intubation and Cuff Inflation","Mean Arterial Pressure","Heart Rate",[2976,2977,2977],"magnesium sulphate","normal saline",{"nctId":2979,"briefTitle":2980,"status":105,"phases":2981,"primaryCompletion":2982,"completion":2982,"start":1049,"enrollment":2983,"conditions":2984,"interventions":2986},"NCT01152476","Emergency Agitation in T&A",[87],"2010-10",42,[2985],"Healthy",[2987,2977],"remifentanil",{"nctId":2989,"briefTitle":2990,"status":1879,"phases":2991,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":22,"conditions":2994,"interventions":2996},"NCT03206008","The Effect of Intraoperative Magnesium Sulfate Infusion on the Postoperative Recovery",[87],"2017-11-24","2016-11-18",[2995],"Postoperative Pain",[2960,1634],{"nctId":2998,"briefTitle":2999,"status":162,"phases":3000,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":188,"conditions":3003,"interventions":3008},"NCT03198338","Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit",[87],"2017-12-31","2017-07-01",[3004,3005,3006,3007],"Colon Neoplasm","Rectum Neoplasm","Perforated Colon","Perforated Bowel",[3009,2552],"0.25% Bupivacaine, 0.5mL\u002Fkg",{"nctId":3011,"briefTitle":3012,"status":105,"phases":3013,"primaryCompletion":3014,"completion":3014,"start":2748,"enrollment":3015,"conditions":3016,"interventions":3018},"NCT01938300","Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery",[87],"2013-10",44,[3017],"Colorectal Cancer",[2960,1634],{"nctId":3020,"briefTitle":3021,"status":105,"phases":3022,"primaryCompletion":2982,"completion":2982,"start":1406,"enrollment":1011,"conditions":3023,"interventions":3025},"NCT01032213","Effect of Magnesium Sulphate on Coagulation",[87],[3024],"Myoma",[2960,2977],{"nctId":3027,"briefTitle":3028,"status":105,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":3032,"conditions":3033,"interventions":3036},"NCT01012063","Perioperative Iron With Erythropoietin in Bilateral Total Knee Replacement Arthroplasty (TKRA)",[87],"2009-10","2008-08",54,[3034,3035],"Anemia","Transfusion",[3037,2977],"iron sucrose, erythropoietin-β",{"nctId":3039,"briefTitle":3040,"status":162,"phases":3041,"primaryCompletion":3042,"completion":1314,"start":3043,"enrollment":109,"conditions":3044,"interventions":3046},"NCT03409835","Effect of Ramosetron on Post-discharge Nausea and Vomiting",[87],"2019-02","2018-03-01",[3045],"Hysteroscopy",[3047,1634],"Ramosetron",{"nctId":3049,"briefTitle":3050,"status":162,"phases":3051,"primaryCompletion":1341,"completion":1341,"start":1700,"enrollment":1095,"conditions":3052,"interventions":3054},"NCT02949310","Effectiveness of Nefopam in Breast Cancer Surgery",[87],[3053],"Breast Neoplasm Malignant Primary",[3055,2552],"Nefopam",{"intervention":2960,"totalTrials":541,"cells":3057},{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3062,"PHASE3":3064,"PHASE4":3066,"NA":3082},{"trials":3059,"activeCount":95},[],{"trials":3061,"activeCount":95},[],{"trials":3063,"activeCount":95},[],{"trials":3065,"activeCount":95},[],{"trials":3067,"activeCount":95},[3068,3078],{"nctId":3069,"briefTitle":3070,"status":162,"phases":3071,"primaryCompletion":1034,"completion":3072,"start":3073,"enrollment":230,"conditions":3074,"interventions":3076},"NCT05237791","Effect of Magnesium on Remifentanil Induced Cough",[86],"2022-12-30","2022-02-03",[3075],"Cough",[3077],"Magnesium sulfate",{"nctId":2952,"briefTitle":2953,"status":105,"phases":3079,"primaryCompletion":2955,"completion":2955,"start":2956,"enrollment":2617,"conditions":3080,"interventions":3081},[86],[2958],[2960,1634],{"trials":3083,"activeCount":95},[3084,3095,3106,3115,3125,3133,3143,3147,3151,3159],{"nctId":3085,"briefTitle":3086,"status":105,"phases":3087,"primaryCompletion":2902,"completion":3088,"start":3089,"enrollment":2435,"conditions":3090,"interventions":3092},"NCT01479751","Comparison of Methods to Facilitate Rapid Sequence Intubation",[87],"2012-08","2011-11",[3091],"Intubating Condition",[2960,3093,3094],"Ketamine","rocuronium",{"nctId":3096,"briefTitle":3097,"status":162,"phases":3098,"primaryCompletion":1047,"completion":1047,"start":3099,"enrollment":109,"conditions":3100,"interventions":3102},"NCT01389791","MgSO4 Combined With Rocuronium Priming",[87],"2011-05",[3101],"Muscle Relaxation",[3103,3104,3105],"magnesium sulfate","priming","magnesium sulfate and priming",{"nctId":3107,"briefTitle":3108,"status":162,"phases":3109,"primaryCompletion":3110,"completion":3110,"start":1987,"enrollment":1272,"conditions":3111,"interventions":3113},"NCT01460563","Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia",[87],"2011-12",[3112],"Cerebral Aneurysm",[2960,3114,3114],"0.9% saline",{"nctId":3116,"briefTitle":3117,"status":105,"phases":3118,"primaryCompletion":3119,"completion":3119,"start":3120,"enrollment":3121,"conditions":3122,"interventions":3124},"NCT04013243","Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade",[87],"2019-07-30","2019-04-26",68,[3123,27],"Magnesium Sulfate Causing Adverse Effects in Therapeutic Use",[2960],{"nctId":3126,"briefTitle":3127,"status":162,"phases":3128,"primaryCompletion":1119,"start":3129,"enrollment":1272,"conditions":3130,"interventions":3132},"NCT01945437","Magnesium and TKA Pain",[87],"2014-01",[3131],"Pain",[2960],{"nctId":3134,"briefTitle":3135,"status":162,"phases":3136,"primaryCompletion":197,"completion":3137,"start":3138,"enrollment":3139,"conditions":3140,"interventions":3142},"NCT05751746","The Effect of Peripartum Magnesium Sulfate Use on the Occurrence of Postpartum Depression",[],"2024-02-28","2023-01-30",108,[3141],"Postpartum Depression",[3077],{"nctId":2989,"briefTitle":2990,"status":1879,"phases":3144,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":22,"conditions":3145,"interventions":3146},[87],[2995],[2960,1634],{"nctId":3011,"briefTitle":3012,"status":105,"phases":3148,"primaryCompletion":3014,"completion":3014,"start":2748,"enrollment":3015,"conditions":3149,"interventions":3150},[87],[3017],[2960,1634],{"nctId":3152,"briefTitle":3153,"status":162,"phases":3154,"primaryCompletion":1316,"completion":1316,"start":253,"enrollment":3155,"conditions":3156,"interventions":3157},"NCT02087202","Hyperalgesia and NMDA Receptor Antagonist",[87],90,[3131],[2960,3158],"ketamine",{"nctId":3020,"briefTitle":3021,"status":105,"phases":3160,"primaryCompletion":2982,"completion":2982,"start":1406,"enrollment":1011,"conditions":3161,"interventions":3162},[87],[3024],[2960,2977],{"intervention":3164,"totalTrials":984,"cells":3165},"Sugammadex",{"EARLY_PHASE1":3166,"PHASE1":3168,"PHASE2":3170,"PHASE3":3172,"PHASE4":3174,"NA":3208},{"trials":3167,"activeCount":95},[],{"trials":3169,"activeCount":95},[],{"trials":3171,"activeCount":95},[],{"trials":3173,"activeCount":95},[],{"trials":3175,"activeCount":95},[3176,3185,3198],{"nctId":3177,"briefTitle":3178,"status":105,"phases":3179,"primaryCompletion":3180,"completion":3180,"start":3181,"enrollment":3139,"conditions":3182,"interventions":3183},"NCT03039543","Neuromuscular Blockade During Transurethral Resection of Bladder Cancer",[86],"2017-11-10","2017-06-01",[27],[3184,3164],"Rocuronium",{"nctId":3186,"briefTitle":3187,"status":105,"phases":3188,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":3191,"conditions":3192,"interventions":3197},"NCT04332627","Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine",[86],"2020-05-21","2020-02-24",77,[3193,3164,3194,3195,3196],"Neuromuscular Blockade Reversal Agent","Neostigmine","Quality of Recovery","Laparoscopic Cholecystectomy",[3164,3194],{"nctId":3199,"briefTitle":3200,"status":105,"phases":3201,"primaryCompletion":3202,"completion":3203,"start":3204,"enrollment":2274,"conditions":3205,"interventions":3206},"NCT02580188","The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery",[86],"2016-06-16","2016-06-18","2015-03-24",[27],[3207],"sugammadex",{"trials":3209,"activeCount":95},[3210],{"nctId":3211,"briefTitle":3212,"status":105,"phases":3213,"primaryCompletion":3214,"completion":3214,"start":3215,"enrollment":438,"conditions":3216,"interventions":3218},"NCT03292965","Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery",[87],"2017-11-29","2017-09-28",[3217],"Neuromuscular Block, Residual",[3194,3164],{"intervention":3220,"totalTrials":984,"cells":3221},"Metronidazole",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3228,"PHASE4":3230,"NA":3240},{"trials":3223,"activeCount":95},[],{"trials":3225,"activeCount":95},[],{"trials":3227,"activeCount":95},[],{"trials":3229,"activeCount":95},[],{"trials":3231,"activeCount":95},[3232,3236],{"nctId":1205,"briefTitle":1206,"status":105,"phases":3233,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":3234,"interventions":3235},[86],[31],[1213,1214,1192],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3237,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":3238,"interventions":3239},[86],[1223],[1192,1225,1214,1226,1227,1228],{"trials":3241,"activeCount":95},[3242,3254],{"nctId":3243,"briefTitle":3244,"status":105,"phases":3245,"primaryCompletion":3246,"completion":1009,"start":1316,"enrollment":3247,"conditions":3248,"interventions":3249},"NCT02159976","Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea",[87],"2015-05",390,[31],[3250,3251,1213,3220,3252,3253],"Pantoprazole","Amoxicillin","Tetracycline","Bismuth",{"nctId":3255,"briefTitle":3256,"status":1879,"phases":3257,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":3260,"interventions":3261},"NCT02359331","The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection",[87],"2022-12-01",370,[854],[3262,3220,3252,1225,3263,3264,3251],"14 days empirical bismuth quadruple therapy","7 days tailored therapy Proton Pump Inhibitor","Moxifloxacin",{"intervention":3266,"totalTrials":984,"cells":3267},"Dexmedetomidine",{"EARLY_PHASE1":3268,"PHASE1":3270,"PHASE2":3272,"PHASE3":3274,"PHASE4":3276,"NA":3287},{"trials":3269,"activeCount":95},[],{"trials":3271,"activeCount":95},[],{"trials":3273,"activeCount":95},[],{"trials":3275,"activeCount":95},[],{"trials":3277,"activeCount":95},[3278],{"nctId":3279,"briefTitle":3280,"status":105,"phases":3281,"primaryCompletion":1699,"completion":1699,"start":2135,"enrollment":3282,"conditions":3283,"interventions":3285},"NCT02784626","Intraoperative Sedatives and Postoperative Pain",[86],48,[3284],"Arthritis, Degenerative",[3266,3286],"Propofol",{"trials":3288,"activeCount":95},[3289,3299,3308],{"nctId":3290,"briefTitle":3291,"status":105,"phases":3292,"primaryCompletion":3293,"completion":3293,"start":1556,"enrollment":3294,"conditions":3295,"interventions":3298},"NCT03251651","Intraoperative Sedatives and Postoperative Deilirium",[87],"2021-10-15",748,[3296,3297,3286,3266],"Lower Extremity Problem","Delirium",[3286,3266],{"nctId":3300,"briefTitle":3301,"status":105,"phases":3302,"primaryCompletion":3303,"completion":3303,"start":229,"enrollment":3304,"conditions":3305,"interventions":3307},"NCT02993718","Sedation by Dexmedetomidine and Propofol",[87],"2017-06",52,[3306],"Anesthesia, Spinal",[3266,3286],{"nctId":3309,"briefTitle":3310,"status":105,"phases":3311,"primaryCompletion":3312,"completion":3312,"start":1856,"enrollment":3313,"conditions":3314,"interventions":3316},"NCT02573558","Intraoperative Sedation and Postoperative Delirium",[],"2016-01",855,[3315],"Orthopedics",[3266,3286],{"intervention":3286,"totalTrials":984,"cells":3318},{"EARLY_PHASE1":3319,"PHASE1":3321,"PHASE2":3323,"PHASE3":3325,"PHASE4":3327,"NA":3333},{"trials":3320,"activeCount":95},[],{"trials":3322,"activeCount":95},[],{"trials":3324,"activeCount":95},[],{"trials":3326,"activeCount":95},[],{"trials":3328,"activeCount":95},[3329],{"nctId":3279,"briefTitle":3280,"status":105,"phases":3330,"primaryCompletion":1699,"completion":1699,"start":2135,"enrollment":3282,"conditions":3331,"interventions":3332},[86],[3284],[3266,3286],{"trials":3334,"activeCount":95},[3335,3339,3343],{"nctId":3290,"briefTitle":3291,"status":105,"phases":3336,"primaryCompletion":3293,"completion":3293,"start":1556,"enrollment":3294,"conditions":3337,"interventions":3338},[87],[3296,3297,3286,3266],[3286,3266],{"nctId":3300,"briefTitle":3301,"status":105,"phases":3340,"primaryCompletion":3303,"completion":3303,"start":229,"enrollment":3304,"conditions":3341,"interventions":3342},[87],[3306],[3266,3286],{"nctId":3309,"briefTitle":3310,"status":105,"phases":3344,"primaryCompletion":3312,"completion":3312,"start":1856,"enrollment":3313,"conditions":3345,"interventions":3346},[],[3315],[3266,3286],{"intervention":3184,"totalTrials":91,"cells":3348},{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3353,"PHASE3":3355,"PHASE4":3357,"NA":3363},{"trials":3350,"activeCount":95},[],{"trials":3352,"activeCount":95},[],{"trials":3354,"activeCount":95},[],{"trials":3356,"activeCount":95},[],{"trials":3358,"activeCount":95},[3359],{"nctId":3177,"briefTitle":3178,"status":105,"phases":3360,"primaryCompletion":3180,"completion":3180,"start":3181,"enrollment":3139,"conditions":3361,"interventions":3362},[86],[27],[3184,3164],{"trials":3364,"activeCount":95},[3365,3369],{"nctId":3085,"briefTitle":3086,"status":105,"phases":3366,"primaryCompletion":2902,"completion":3088,"start":3089,"enrollment":2435,"conditions":3367,"interventions":3368},[87],[3091],[2960,3093,3094],{"nctId":3370,"briefTitle":3371,"status":105,"phases":3372,"primaryCompletion":3373,"completion":3373,"start":3374,"enrollment":1272,"conditions":3375,"interventions":3377},"NCT02575443","Neuromuscular Block and Anesthetic Depth Monitoring",[87],"2017-09","2015-09",[3376],"Cholecystectomy, Laparoscopic",[3184,3184],{"intervention":3251,"totalTrials":91,"cells":3379},{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3384,"PHASE3":3386,"PHASE4":3388,"NA":3394},{"trials":3381,"activeCount":95},[],{"trials":3383,"activeCount":95},[],{"trials":3385,"activeCount":95},[],{"trials":3387,"activeCount":95},[],{"trials":3389,"activeCount":95},[3390],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3391,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":3392,"interventions":3393},[86],[1223],[1192,1225,1214,1226,1227,1228],{"trials":3395,"activeCount":95},[3396,3400],{"nctId":3243,"briefTitle":3244,"status":105,"phases":3397,"primaryCompletion":3246,"completion":1009,"start":1316,"enrollment":3247,"conditions":3398,"interventions":3399},[87],[31],[3250,3251,1213,3220,3252,3253],{"nctId":3255,"briefTitle":3256,"status":1879,"phases":3401,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":3402,"interventions":3403},[87],[854],[3262,3220,3252,1225,3263,3264,3251],{"intervention":3252,"totalTrials":91,"cells":3405},{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3420},{"trials":3407,"activeCount":95},[],{"trials":3409,"activeCount":95},[],{"trials":3411,"activeCount":95},[],{"trials":3413,"activeCount":95},[],{"trials":3415,"activeCount":95},[3416],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3417,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":3418,"interventions":3419},[86],[1223],[1192,1225,1214,1226,1227,1228],{"trials":3421,"activeCount":95},[3422,3426],{"nctId":3243,"briefTitle":3244,"status":105,"phases":3423,"primaryCompletion":3246,"completion":1009,"start":1316,"enrollment":3247,"conditions":3424,"interventions":3425},[87],[31],[3250,3251,1213,3220,3252,3253],{"nctId":3255,"briefTitle":3256,"status":1879,"phases":3427,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":3428,"interventions":3429},[87],[854],[3262,3220,3252,1225,3263,3264,3251],{"intervention":3055,"totalTrials":91,"cells":3431},{"EARLY_PHASE1":3432,"PHASE1":3434,"PHASE2":3436,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3433,"activeCount":95},[],{"trials":3435,"activeCount":95},[],{"trials":3437,"activeCount":95},[],{"trials":3439,"activeCount":95},[],{"trials":3441,"activeCount":95},[],{"trials":3443,"activeCount":95},[3444,3453,3457],{"nctId":3445,"briefTitle":3446,"status":105,"phases":3447,"primaryCompletion":3312,"completion":3312,"start":3448,"enrollment":1513,"conditions":3449,"interventions":3451},"NCT02561468","The Preemptive Analgesic Efficacy of Nefopam",[87],"2015-04",[3450],"Breast Neoplasm",[3055,3452],"Saline",{"nctId":3049,"briefTitle":3050,"status":162,"phases":3454,"primaryCompletion":1341,"completion":1341,"start":1700,"enrollment":1095,"conditions":3455,"interventions":3456},[87],[3053],[3055,2552],{"nctId":3458,"briefTitle":3459,"status":105,"phases":3460,"primaryCompletion":3461,"completion":3461,"start":1701,"enrollment":230,"conditions":3462,"interventions":3464},"NCT02561494","Postoperative Analgesic Effect of Nefopam",[87],"2016-08",[3463],"Stomach Neoplasms",[3055,3452],{"intervention":2976,"totalTrials":141,"cells":3466},{"EARLY_PHASE1":3467,"PHASE1":3469,"PHASE2":3471,"PHASE3":3473,"PHASE4":3475,"NA":3477},{"trials":3468,"activeCount":95},[],{"trials":3470,"activeCount":95},[],{"trials":3472,"activeCount":95},[],{"trials":3474,"activeCount":95},[],{"trials":3476,"activeCount":95},[],{"trials":3478,"activeCount":95},[3479,3483],{"nctId":2964,"briefTitle":2965,"status":105,"phases":3480,"primaryCompletion":2967,"completion":2967,"start":1219,"enrollment":2968,"conditions":3481,"interventions":3482},[87],[2970,2971,2972,2973,2974],[2976,2977,2977],{"nctId":3484,"briefTitle":3485,"status":105,"phases":3486,"primaryCompletion":2967,"completion":2967,"start":1219,"enrollment":3487,"conditions":3488,"interventions":3491},"NCT01360060","Analgesia After Cesarean Section",[],503,[3489,3490],"Preeclampsia","Pregnancy",[3492],"Magnesium Sulphate",{"intervention":3250,"totalTrials":141,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3496,"activeCount":95},[],{"trials":3498,"activeCount":95},[],{"trials":3500,"activeCount":95},[],{"trials":3502,"activeCount":95},[],{"trials":3504,"activeCount":95},[],{"trials":3506,"activeCount":95},[3507,3516],{"nctId":3508,"briefTitle":3509,"status":105,"phases":3510,"primaryCompletion":3246,"completion":3246,"start":3511,"enrollment":2983,"conditions":3512,"interventions":3514},"NCT02733640","Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?",[87],"2012-10",[3513],"Antiplatelet Effect",[3250,3515],"Ranitidine",{"nctId":3243,"briefTitle":3244,"status":105,"phases":3517,"primaryCompletion":3246,"completion":1009,"start":1316,"enrollment":3247,"conditions":3518,"interventions":3519},[87],[31],[3250,3251,1213,3220,3252,3253],{"intervention":3521,"totalTrials":141,"cells":3522},"Dexamethasone",{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3527,"PHASE3":3529,"PHASE4":3531,"NA":3533},{"trials":3524,"activeCount":95},[],{"trials":3526,"activeCount":95},[],{"trials":3528,"activeCount":95},[],{"trials":3530,"activeCount":95},[],{"trials":3532,"activeCount":95},[],{"trials":3534,"activeCount":95},[3535,3543],{"nctId":3536,"briefTitle":3537,"status":105,"phases":3538,"primaryCompletion":1133,"completion":1133,"start":3539,"enrollment":131,"conditions":3540,"interventions":3542},"NCT03177317","Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapy",[87],"2017-05-01",[3541],"Colonic Neoplasms",[3521],{"nctId":3544,"briefTitle":3545,"status":105,"phases":3546,"primaryCompletion":3547,"completion":3448,"start":3014,"enrollment":852,"conditions":3548,"interventions":3551},"NCT01885481","Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone",[87],"2015-02",[3549,3550],"Back Pain","Neck Pain",[3521,3552],"Betamethasone",{"intervention":1082,"totalTrials":141,"cells":3554},{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3559,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3556,"activeCount":95},[],{"trials":3558,"activeCount":95},[],{"trials":3560,"activeCount":95},[],{"trials":3562,"activeCount":95},[],{"trials":3564,"activeCount":95},[],{"trials":3566,"activeCount":95},[3567,3577],{"nctId":3568,"briefTitle":3569,"status":105,"phases":3570,"primaryCompletion":164,"completion":164,"start":3571,"enrollment":3572,"conditions":3573,"interventions":3576},"NCT05320016","Effects of Remimazolam on Quality of Recovery After Ambulatory Surgery",[],"2021-11-01",38,[3574,3575,3195,1082],"Day Surgery","Patient Outcome Assessment",[1082],{"nctId":3578,"briefTitle":3579,"status":105,"phases":3580,"primaryCompletion":3581,"completion":3581,"start":3571,"enrollment":3572,"conditions":3582,"interventions":3586},"NCT05025410","Remimazolam and Remifentanil Without Neuromuscular Blocking Agent",[],"2022-01-31",[3583,3584,3585],"Myoma;Uterus","Polyp Endometrium","Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle",[1082],{"intervention":3093,"totalTrials":141,"cells":3588},{"EARLY_PHASE1":3589,"PHASE1":3591,"PHASE2":3593,"PHASE3":3595,"PHASE4":3597,"NA":3599},{"trials":3590,"activeCount":95},[],{"trials":3592,"activeCount":95},[],{"trials":3594,"activeCount":95},[],{"trials":3596,"activeCount":95},[],{"trials":3598,"activeCount":95},[],{"trials":3600,"activeCount":95},[3601,3605],{"nctId":3085,"briefTitle":3086,"status":105,"phases":3602,"primaryCompletion":2902,"completion":3088,"start":3089,"enrollment":2435,"conditions":3603,"interventions":3604},[87],[3091],[2960,3093,3094],{"nctId":3152,"briefTitle":3153,"status":162,"phases":3606,"primaryCompletion":1316,"completion":1316,"start":253,"enrollment":3155,"conditions":3607,"interventions":3608},[87],[3131],[2960,3158],{"intervention":3610,"totalTrials":141,"cells":3611},"Fimasartan",{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3618,"PHASE4":3620,"NA":3630},{"trials":3613,"activeCount":95},[],{"trials":3615,"activeCount":95},[],{"trials":3617,"activeCount":95},[],{"trials":3619,"activeCount":95},[],{"trials":3621,"activeCount":95},[3622],{"nctId":3623,"briefTitle":3624,"status":162,"phases":3625,"primaryCompletion":2817,"completion":197,"start":3626,"enrollment":2983,"conditions":3627,"interventions":3629},"NCT05173025","Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension",[86],"2018-01-01",[34,122,304,3628],"Renin Hypertension",[3610],{"trials":3631,"activeCount":95},[3632],{"nctId":3633,"briefTitle":3634,"status":105,"phases":3635,"primaryCompletion":3636,"completion":3637,"start":3638,"enrollment":3639,"conditions":3640,"interventions":3642},"NCT03219632","Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG",[],"2017-04-30","2017-05-30","2012-06-05",72,[3641,34],"Left Ventricular Hypertrophy",[3610],{"intervention":3194,"totalTrials":141,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3651,"PHASE4":3653,"NA":3659},{"trials":3646,"activeCount":95},[],{"trials":3648,"activeCount":95},[],{"trials":3650,"activeCount":95},[],{"trials":3652,"activeCount":95},[],{"trials":3654,"activeCount":95},[3655],{"nctId":3186,"briefTitle":3187,"status":105,"phases":3656,"primaryCompletion":3189,"completion":3189,"start":3190,"enrollment":3191,"conditions":3657,"interventions":3658},[86],[3193,3164,3194,3195,3196],[3164,3194],{"trials":3660,"activeCount":95},[3661],{"nctId":3211,"briefTitle":3212,"status":105,"phases":3662,"primaryCompletion":3214,"completion":3214,"start":3215,"enrollment":438,"conditions":3663,"interventions":3664},[87],[3217],[3194,3164],{"intervention":3666,"totalTrials":141,"cells":3667},"Combined exercise and nutrition intervention",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3678},{"trials":3669,"activeCount":95},[],{"trials":3671,"activeCount":95},[],{"trials":3673,"activeCount":95},[],{"trials":3675,"activeCount":95},[],{"trials":3677,"activeCount":95},[],{"trials":3679,"activeCount":95},[3680,3690],{"nctId":3681,"briefTitle":3682,"status":105,"phases":3683,"primaryCompletion":3684,"completion":3685,"start":3686,"enrollment":2968,"conditions":3687,"interventions":3689},"NCT04948736","Multidisciplinary Combined Exercise and Nutrition Intervention for Sarcopenia",[87],"2024-07-11","2025-07-31","2022-03-08",[3688],"Sarcopenia",[3666],{"nctId":3691,"briefTitle":3692,"status":105,"phases":3693,"primaryCompletion":3685,"completion":3685,"start":3694,"enrollment":438,"conditions":3695,"interventions":3696},"NCT07028294","Multidisciplinary Combined Exercise and Nutrition Intervention for Sarcopenia (2)",[87],"2023-09-04",[3688],[3666],{"intervention":1213,"totalTrials":141,"cells":3698},{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3705,"PHASE4":3707,"NA":3713},{"trials":3700,"activeCount":95},[],{"trials":3702,"activeCount":95},[],{"trials":3704,"activeCount":95},[],{"trials":3706,"activeCount":95},[],{"trials":3708,"activeCount":95},[3709],{"nctId":1205,"briefTitle":1206,"status":105,"phases":3710,"primaryCompletion":1208,"completion":1208,"start":1209,"enrollment":1210,"conditions":3711,"interventions":3712},[86],[31],[1213,1214,1192],{"trials":3714,"activeCount":95},[3715],{"nctId":3243,"briefTitle":3244,"status":105,"phases":3716,"primaryCompletion":3246,"completion":1009,"start":1316,"enrollment":3247,"conditions":3717,"interventions":3718},[87],[31],[3250,3251,1213,3220,3252,3253],{"intervention":2526,"totalTrials":141,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3727,"PHASE4":3733,"NA":3735},{"trials":3722,"activeCount":95},[],{"trials":3724,"activeCount":95},[],{"trials":3726,"activeCount":95},[],{"trials":3728,"activeCount":95},[3729],{"nctId":2516,"briefTitle":2517,"status":105,"phases":3730,"primaryCompletion":2519,"completion":2520,"start":2521,"enrollment":2522,"conditions":3731,"interventions":3732},[85],[2524],[2505,2526],{"trials":3734,"activeCount":95},[],{"trials":3736,"activeCount":95},[3737],{"nctId":3738,"briefTitle":3739,"status":162,"phases":3740,"primaryCompletion":3741,"completion":3742,"start":3312,"enrollment":3743,"conditions":3744,"interventions":3747},"NCT02960828","\"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally\" Study",[87],"2020-05","2020-12",21,[3745,3746],"Age-Related Macular Degeneration","Retinal Drusen",[2526],{"intervention":3452,"totalTrials":141,"cells":3749},{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3751,"activeCount":95},[],{"trials":3753,"activeCount":95},[],{"trials":3755,"activeCount":95},[],{"trials":3757,"activeCount":95},[],{"trials":3759,"activeCount":95},[],{"trials":3761,"activeCount":95},[3762,3766],{"nctId":3445,"briefTitle":3446,"status":105,"phases":3763,"primaryCompletion":3312,"completion":3312,"start":3448,"enrollment":1513,"conditions":3764,"interventions":3765},[87],[3450],[3055,3452],{"nctId":3458,"briefTitle":3459,"status":105,"phases":3767,"primaryCompletion":3461,"completion":3461,"start":1701,"enrollment":230,"conditions":3768,"interventions":3769},[87],[3463],[3055,3452],{"intervention":1225,"totalTrials":141,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3778,"PHASE4":3780,"NA":3786},{"trials":3773,"activeCount":95},[],{"trials":3775,"activeCount":95},[],{"trials":3777,"activeCount":95},[],{"trials":3779,"activeCount":95},[],{"trials":3781,"activeCount":95},[3782],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3783,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":3784,"interventions":3785},[86],[1223],[1192,1225,1214,1226,1227,1228],{"trials":3787,"activeCount":95},[3788],{"nctId":3255,"briefTitle":3256,"status":1879,"phases":3789,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":3790,"interventions":3791},[87],[854],[3262,3220,3252,1225,3263,3264,3251],{"intervention":1227,"totalTrials":141,"cells":3793},{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3800,"PHASE4":3802,"NA":3808},{"trials":3795,"activeCount":95},[],{"trials":3797,"activeCount":95},[],{"trials":3799,"activeCount":95},[],{"trials":3801,"activeCount":95},[],{"trials":3803,"activeCount":95},[3804],{"nctId":1216,"briefTitle":1217,"status":105,"phases":3805,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":3806,"interventions":3807},[86],[1223],[1192,1225,1214,1226,1227,1228],{"trials":3809,"activeCount":95},[3810],{"nctId":3255,"briefTitle":3256,"status":1879,"phases":3811,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":3812,"interventions":3813},[87],[854],[3262,3220,3252,1225,3263,3264,3251],{"intervention":3815,"totalTrials":136,"cells":3816},"Pentaspan, voluven, volulyte",{"EARLY_PHASE1":3817,"PHASE1":3819,"PHASE2":3821,"PHASE3":3823,"PHASE4":3825,"NA":3827},{"trials":3818,"activeCount":95},[],{"trials":3820,"activeCount":95},[],{"trials":3822,"activeCount":95},[],{"trials":3824,"activeCount":95},[],{"trials":3826,"activeCount":95},[],{"trials":3828,"activeCount":95},[3829],{"nctId":3830,"briefTitle":3831,"status":105,"phases":3832,"primaryCompletion":1557,"completion":1557,"start":1047,"enrollment":3833,"conditions":3834,"interventions":3837},"NCT01512628","Rotational Thromboelstometry (ROTEM) change_colloid_total Hip Replacement Arthroplasty",[87],75,[3835,3836],"Avascular Necrosis of Hip","Total Hip Replacement Arthroplasty",[3815],{"intervention":3839,"totalTrials":136,"cells":3840},"0 ul of palonosetron",{"EARLY_PHASE1":3841,"PHASE1":3843,"PHASE2":3845,"PHASE3":3847,"PHASE4":3849,"NA":3851},{"trials":3842,"activeCount":95},[],{"trials":3844,"activeCount":95},[],{"trials":3846,"activeCount":95},[],{"trials":3848,"activeCount":95},[],{"trials":3850,"activeCount":95},[],{"trials":3852,"activeCount":95},[3853],{"nctId":3854,"briefTitle":3855,"status":162,"phases":3856,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":3860,"interventions":3862},"NCT04507711","Palonosetron and Blood Coagulation",[87],"2023-11-15","2023-12-15","2020-09-16",[3861],"Blood Coagulation Disorder",[3839,3863,3864,3865],"1 ul of palonosetron","10 ul of palonosetron","100 ul of palonosetron",{"intervention":3863,"totalTrials":136,"cells":3867},{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3869,"activeCount":95},[],{"trials":3871,"activeCount":95},[],{"trials":3873,"activeCount":95},[],{"trials":3875,"activeCount":95},[],{"trials":3877,"activeCount":95},[],{"trials":3879,"activeCount":95},[3880],{"nctId":3854,"briefTitle":3855,"status":162,"phases":3881,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":3882,"interventions":3883},[87],[3861],[3839,3863,3864,3865],{"intervention":3864,"totalTrials":136,"cells":3885},{"EARLY_PHASE1":3886,"PHASE1":3888,"PHASE2":3890,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3887,"activeCount":95},[],{"trials":3889,"activeCount":95},[],{"trials":3891,"activeCount":95},[],{"trials":3893,"activeCount":95},[],{"trials":3895,"activeCount":95},[],{"trials":3897,"activeCount":95},[3898],{"nctId":3854,"briefTitle":3855,"status":162,"phases":3899,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":3900,"interventions":3901},[87],[3861],[3839,3863,3864,3865],{"intervention":3865,"totalTrials":136,"cells":3903},{"EARLY_PHASE1":3904,"PHASE1":3906,"PHASE2":3908,"PHASE3":3910,"PHASE4":3912,"NA":3914},{"trials":3905,"activeCount":95},[],{"trials":3907,"activeCount":95},[],{"trials":3909,"activeCount":95},[],{"trials":3911,"activeCount":95},[],{"trials":3913,"activeCount":95},[],{"trials":3915,"activeCount":95},[3916],{"nctId":3854,"briefTitle":3855,"status":162,"phases":3917,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":3918,"interventions":3919},[87],[3861],[3839,3863,3864,3865],{"intervention":3921,"totalTrials":136,"cells":3922},"PPI triple therapy",{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3927,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3924,"activeCount":95},[],{"trials":3926,"activeCount":95},[],{"trials":3928,"activeCount":95},[],{"trials":3930,"activeCount":95},[],{"trials":3932,"activeCount":95},[],{"trials":3934,"activeCount":95},[3935],{"nctId":3936,"briefTitle":3937,"status":105,"phases":3938,"primaryCompletion":1405,"completion":1405,"start":1220,"enrollment":3939,"conditions":3940,"interventions":3941},"NCT01922505","Eradication Rates of Helicobacter Pylori and Its Affecting Factors",[],2500,[1223],[3921],{"intervention":3943,"totalTrials":136,"cells":3944},"0 ul of ondansetron",{"EARLY_PHASE1":3945,"PHASE1":3947,"PHASE2":3949,"PHASE3":3951,"PHASE4":3953,"NA":3955},{"trials":3946,"activeCount":95},[],{"trials":3948,"activeCount":95},[],{"trials":3950,"activeCount":95},[],{"trials":3952,"activeCount":95},[],{"trials":3954,"activeCount":95},[],{"trials":3956,"activeCount":95},[3957],{"nctId":3958,"briefTitle":3959,"status":162,"phases":3960,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":3961,"interventions":3962},"NCT04499274","Ondansetron and Blood Coagulation",[87],[3861],[3943,3963,3964,3965],"0.2 ul of ondansetron","2 ul of ondansetron","20 ul of ondansetron",{"intervention":3963,"totalTrials":136,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3974,"PHASE4":3976,"NA":3978},{"trials":3969,"activeCount":95},[],{"trials":3971,"activeCount":95},[],{"trials":3973,"activeCount":95},[],{"trials":3975,"activeCount":95},[],{"trials":3977,"activeCount":95},[],{"trials":3979,"activeCount":95},[3980],{"nctId":3958,"briefTitle":3959,"status":162,"phases":3981,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":3982,"interventions":3983},[87],[3861],[3943,3963,3964,3965],{"intervention":3964,"totalTrials":136,"cells":3985},{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3987,"activeCount":95},[],{"trials":3989,"activeCount":95},[],{"trials":3991,"activeCount":95},[],{"trials":3993,"activeCount":95},[],{"trials":3995,"activeCount":95},[],{"trials":3997,"activeCount":95},[3998],{"nctId":3958,"briefTitle":3959,"status":162,"phases":3999,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":4000,"interventions":4001},[87],[3861],[3943,3963,3964,3965],{"intervention":3965,"totalTrials":136,"cells":4003},{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4008,"PHASE3":4010,"PHASE4":4012,"NA":4014},{"trials":4005,"activeCount":95},[],{"trials":4007,"activeCount":95},[],{"trials":4009,"activeCount":95},[],{"trials":4011,"activeCount":95},[],{"trials":4013,"activeCount":95},[],{"trials":4015,"activeCount":95},[4016],{"nctId":3958,"briefTitle":3959,"status":162,"phases":4017,"primaryCompletion":3857,"completion":3858,"start":3859,"enrollment":541,"conditions":4018,"interventions":4019},[87],[3861],[3943,3963,3964,3965],{"intervention":4021,"totalTrials":136,"cells":4022},"Helicobacter pylori eradication",{"EARLY_PHASE1":4023,"PHASE1":4025,"PHASE2":4027,"PHASE3":4029,"PHASE4":4031,"NA":4033},{"trials":4024,"activeCount":95},[],{"trials":4026,"activeCount":95},[],{"trials":4028,"activeCount":95},[],{"trials":4030,"activeCount":95},[],{"trials":4032,"activeCount":95},[],{"trials":4034,"activeCount":95},[4035],{"nctId":4036,"briefTitle":4037,"status":105,"phases":4038,"primaryCompletion":4039,"completion":4040,"start":4041,"enrollment":4042,"conditions":4043,"interventions":4044},"NCT03978481","Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study",[],"2020-01-30","2020-04-30","2019-01-30",3700,[18],[4021],{"intervention":3515,"totalTrials":136,"cells":4046},{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4051,"PHASE3":4053,"PHASE4":4055,"NA":4057},{"trials":4048,"activeCount":95},[],{"trials":4050,"activeCount":95},[],{"trials":4052,"activeCount":95},[],{"trials":4054,"activeCount":95},[],{"trials":4056,"activeCount":95},[],{"trials":4058,"activeCount":95},[4059],{"nctId":3508,"briefTitle":3509,"status":105,"phases":4060,"primaryCompletion":3246,"completion":3246,"start":3511,"enrollment":2983,"conditions":4061,"interventions":4062},[87],[3513],[3250,3515],{"intervention":4064,"totalTrials":136,"cells":4065},"Amosartan",{"EARLY_PHASE1":4066,"PHASE1":4068,"PHASE2":4070,"PHASE3":4072,"PHASE4":4074,"NA":4076},{"trials":4067,"activeCount":95},[],{"trials":4069,"activeCount":95},[],{"trials":4071,"activeCount":95},[],{"trials":4073,"activeCount":95},[],{"trials":4075,"activeCount":95},[],{"trials":4077,"activeCount":95},[4078],{"nctId":4079,"briefTitle":4080,"status":105,"phases":4081,"primaryCompletion":4082,"completion":4083,"start":1926,"enrollment":131,"conditions":4084,"interventions":4085},"NCT03255551","Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure",[],"2015-06-30","2015-12-31",[34],[4064],{"intervention":4087,"totalTrials":136,"cells":4088},"labetalol",{"EARLY_PHASE1":4089,"PHASE1":4091,"PHASE2":4093,"PHASE3":4095,"PHASE4":4097,"NA":4099},{"trials":4090,"activeCount":95},[],{"trials":4092,"activeCount":95},[],{"trials":4094,"activeCount":95},[],{"trials":4096,"activeCount":95},[],{"trials":4098,"activeCount":95},[],{"trials":4100,"activeCount":95},[4101],{"nctId":4102,"briefTitle":4103,"status":162,"phases":4104,"primaryCompletion":4105,"start":4106,"enrollment":2274,"conditions":4107,"interventions":4110},"NCT01041066","Nicardipine Versus Labetalol During Intubation",[87],"2009-12","2009-09",[4108,4109],"Patients Who Are Intubated for General Anesthesia","Endotracheal Intubation",[4087,4111],"nicardipine",{"intervention":4111,"totalTrials":136,"cells":4113},{"EARLY_PHASE1":4114,"PHASE1":4116,"PHASE2":4118,"PHASE3":4120,"PHASE4":4122,"NA":4124},{"trials":4115,"activeCount":95},[],{"trials":4117,"activeCount":95},[],{"trials":4119,"activeCount":95},[],{"trials":4121,"activeCount":95},[],{"trials":4123,"activeCount":95},[],{"trials":4125,"activeCount":95},[4126],{"nctId":4102,"briefTitle":4103,"status":162,"phases":4127,"primaryCompletion":4105,"start":4106,"enrollment":2274,"conditions":4128,"interventions":4129},[87],[4108,4109],[4087,4111],{"intervention":4131,"totalTrials":136,"cells":4132},"intravenous ramosetron",{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4139,"PHASE4":4141,"NA":4143},{"trials":4134,"activeCount":95},[],{"trials":4136,"activeCount":95},[],{"trials":4138,"activeCount":95},[],{"trials":4140,"activeCount":95},[],{"trials":4142,"activeCount":95},[],{"trials":4144,"activeCount":95},[4145],{"nctId":4146,"briefTitle":4147,"status":162,"phases":4148,"primaryCompletion":4105,"start":2775,"enrollment":120,"conditions":4149,"interventions":4152},"NCT01041183","The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy",[87],[4150,4151,3196],"Nausea","Vomiting",[4131,4153,4154],"oral ramosetron","oral and IV ramosetron",{"intervention":4153,"totalTrials":136,"cells":4156},{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4158,"activeCount":95},[],{"trials":4160,"activeCount":95},[],{"trials":4162,"activeCount":95},[],{"trials":4164,"activeCount":95},[],{"trials":4166,"activeCount":95},[],{"trials":4168,"activeCount":95},[4169],{"nctId":4146,"briefTitle":4147,"status":162,"phases":4170,"primaryCompletion":4105,"start":2775,"enrollment":120,"conditions":4171,"interventions":4172},[87],[4150,4151,3196],[4131,4153,4154],{"intervention":4154,"totalTrials":136,"cells":4174},{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4176,"activeCount":95},[],{"trials":4178,"activeCount":95},[],{"trials":4180,"activeCount":95},[],{"trials":4182,"activeCount":95},[],{"trials":4184,"activeCount":95},[],{"trials":4186,"activeCount":95},[4187],{"nctId":4146,"briefTitle":4147,"status":162,"phases":4188,"primaryCompletion":4105,"start":2775,"enrollment":120,"conditions":4189,"interventions":4190},[87],[4150,4151,3196],[4131,4153,4154],{"intervention":4192,"totalTrials":136,"cells":4193},"Mutation",{"EARLY_PHASE1":4194,"PHASE1":4196,"PHASE2":4198,"PHASE3":4200,"PHASE4":4202,"NA":4204},{"trials":4195,"activeCount":95},[],{"trials":4197,"activeCount":95},[],{"trials":4199,"activeCount":95},[],{"trials":4201,"activeCount":95},[],{"trials":4203,"activeCount":95},[],{"trials":4205,"activeCount":95},[4206],{"nctId":4207,"briefTitle":4208,"status":105,"phases":4209,"primaryCompletion":164,"completion":164,"start":4210,"enrollment":4211,"conditions":4212,"interventions":4213},"NCT05657210","Prognostic Value of Each Codon-specific KRAS Mutation in Colorectal Cancer",[],"2009-01-01",2203,[3017],[4192],{"intervention":4215,"totalTrials":136,"cells":4216},"Tranexamic Acid",{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4221,"PHASE3":4223,"PHASE4":4225,"NA":4227},{"trials":4218,"activeCount":95},[],{"trials":4220,"activeCount":95},[],{"trials":4222,"activeCount":95},[],{"trials":4224,"activeCount":95},[],{"trials":4226,"activeCount":95},[],{"trials":4228,"activeCount":95},[4229],{"nctId":4230,"briefTitle":4231,"status":105,"phases":4232,"primaryCompletion":3246,"completion":3246,"start":4233,"enrollment":1272,"conditions":4234,"interventions":4236},"NCT02146456","Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion",[87],"2014-05",[2437,4235],"Degenerative Arthritis of Hip",[4215],{"intervention":4238,"totalTrials":136,"cells":4239},"post-myocardial infarction management",{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4241,"activeCount":95},[],{"trials":4243,"activeCount":95},[],{"trials":4245,"activeCount":95},[],{"trials":4247,"activeCount":95},[],{"trials":4249,"activeCount":95},[],{"trials":4251,"activeCount":95},[4252],{"nctId":4253,"briefTitle":4254,"status":162,"phases":4255,"primaryCompletion":4256,"completion":4256,"start":4257,"enrollment":3121,"conditions":4258,"interventions":4260},"NCT04012541","Comprehensive Oral Intervention in Patients With AMI",[87],"2021-03-31","2019-07-05",[2161,4259],"Dental Diseases",[4238],{"intervention":4262,"totalTrials":136,"cells":4263},"use of rocuronium when the LMA is inserted",{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4270,"PHASE4":4272,"NA":4274},{"trials":4265,"activeCount":95},[],{"trials":4267,"activeCount":95},[],{"trials":4269,"activeCount":95},[],{"trials":4271,"activeCount":95},[],{"trials":4273,"activeCount":95},[],{"trials":4275,"activeCount":95},[4276],{"nctId":4277,"briefTitle":4278,"status":105,"phases":4279,"primaryCompletion":1049,"completion":1049,"start":4280,"enrollment":4281,"conditions":4282,"interventions":4284},"NCT01035021","Neuromuscular Block in Laryngeal Mask Airway(LMA) Insertion",[87],"2009-06",160,[1086,4283],"Breast Disease",[4262],{"intervention":3104,"totalTrials":136,"cells":4286},{"EARLY_PHASE1":4287,"PHASE1":4289,"PHASE2":4291,"PHASE3":4293,"PHASE4":4295,"NA":4297},{"trials":4288,"activeCount":95},[],{"trials":4290,"activeCount":95},[],{"trials":4292,"activeCount":95},[],{"trials":4294,"activeCount":95},[],{"trials":4296,"activeCount":95},[],{"trials":4298,"activeCount":95},[4299],{"nctId":3096,"briefTitle":3097,"status":162,"phases":4300,"primaryCompletion":1047,"completion":1047,"start":3099,"enrollment":109,"conditions":4301,"interventions":4302},[87],[3101],[3103,3104,3105],{"intervention":3105,"totalTrials":136,"cells":4304},{"EARLY_PHASE1":4305,"PHASE1":4307,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4306,"activeCount":95},[],{"trials":4308,"activeCount":95},[],{"trials":4310,"activeCount":95},[],{"trials":4312,"activeCount":95},[],{"trials":4314,"activeCount":95},[],{"trials":4316,"activeCount":95},[4317],{"nctId":3096,"briefTitle":3097,"status":162,"phases":4318,"primaryCompletion":1047,"completion":1047,"start":3099,"enrollment":109,"conditions":4319,"interventions":4320},[87],[3101],[3103,3104,3105],{"intervention":4322,"totalTrials":136,"cells":4323},"Spinal Steroid",{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4330,"PHASE4":4332,"NA":4334},{"trials":4325,"activeCount":95},[],{"trials":4327,"activeCount":95},[],{"trials":4329,"activeCount":95},[],{"trials":4331,"activeCount":95},[],{"trials":4333,"activeCount":95},[],{"trials":4335,"activeCount":95},[4336],{"nctId":4337,"briefTitle":4338,"status":105,"phases":4339,"primaryCompletion":3110,"completion":3110,"start":1987,"enrollment":4340,"conditions":4341,"interventions":4343},"NCT01756196","Incidence of Various Types of Systemic Reactions Related to Spinal Steroid Injection: A Prospective Study",[],997,[4342],"Incidence and Types of Systemic Reactions Occurring After Spinal Steroid Injection in a Large Population",[4322],{"intervention":4345,"totalTrials":136,"cells":4346},"the order of drug administration",{"EARLY_PHASE1":4347,"PHASE1":4349,"PHASE2":4351,"PHASE3":4353,"PHASE4":4355,"NA":4357},{"trials":4348,"activeCount":95},[],{"trials":4350,"activeCount":95},[],{"trials":4352,"activeCount":95},[],{"trials":4354,"activeCount":95},[],{"trials":4356,"activeCount":95},[],{"trials":4358,"activeCount":95},[4359],{"nctId":4360,"briefTitle":4361,"status":105,"phases":4362,"primaryCompletion":2982,"completion":2982,"start":4105,"enrollment":4363,"conditions":4364,"interventions":4366},"NCT01030510","Study of Rocuronium Onset Time According to Remifentanil Infusion",[87],126,[4365],"Anesthesia",[4345],{"intervention":4368,"totalTrials":136,"cells":4369},"CUREAⓇ",{"EARLY_PHASE1":4370,"PHASE1":4372,"PHASE2":4374,"PHASE3":4376,"PHASE4":4378,"NA":4380},{"trials":4371,"activeCount":95},[],{"trials":4373,"activeCount":95},[],{"trials":4375,"activeCount":95},[],{"trials":4377,"activeCount":95},[],{"trials":4379,"activeCount":95},[],{"trials":4381,"activeCount":95},[4382],{"nctId":4383,"briefTitle":4384,"status":105,"phases":4385,"primaryCompletion":4386,"completion":4386,"start":4387,"enrollment":4388,"conditions":4389,"interventions":4391},"NCT06574750","Effect of a New HA Filler in Correcting Nasolabial Fold",[87],"2023-05-08","2021-10-16",74,[4390],"Aging Problems",[4368,4392],"JuvedermⓇ",{"intervention":4392,"totalTrials":136,"cells":4394},{"EARLY_PHASE1":4395,"PHASE1":4397,"PHASE2":4399,"PHASE3":4401,"PHASE4":4403,"NA":4405},{"trials":4396,"activeCount":95},[],{"trials":4398,"activeCount":95},[],{"trials":4400,"activeCount":95},[],{"trials":4402,"activeCount":95},[],{"trials":4404,"activeCount":95},[],{"trials":4406,"activeCount":95},[4407],{"nctId":4383,"briefTitle":4384,"status":105,"phases":4408,"primaryCompletion":4386,"completion":4386,"start":4387,"enrollment":4388,"conditions":4409,"interventions":4410},[87],[4390],[4368,4392],{"intervention":4412,"totalTrials":136,"cells":4413},"Propofol, remifentanil",{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4420,"PHASE4":4422,"NA":4424},{"trials":4415,"activeCount":95},[],{"trials":4417,"activeCount":95},[],{"trials":4419,"activeCount":95},[],{"trials":4421,"activeCount":95},[],{"trials":4423,"activeCount":95},[],{"trials":4425,"activeCount":95},[4426],{"nctId":4427,"briefTitle":4428,"status":105,"phases":4429,"primaryCompletion":4430,"completion":4430,"start":4431,"enrollment":4432,"conditions":4433,"interventions":4439},"NCT02151305","Different Hemostasis According to the Anesthetic Agents",[87],"2012-04","2010-08",66,[4434,4435,4436,4437,4438],"Cataract","Retina Detachment","Pterygium","Keratitis","Vitreous Hemorrhage",[4412,4440],"Sevoflurane",{"intervention":4440,"totalTrials":136,"cells":4442},{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4444,"activeCount":95},[],{"trials":4446,"activeCount":95},[],{"trials":4448,"activeCount":95},[],{"trials":4450,"activeCount":95},[],{"trials":4452,"activeCount":95},[],{"trials":4454,"activeCount":95},[4455],{"nctId":4427,"briefTitle":4428,"status":105,"phases":4456,"primaryCompletion":4430,"completion":4430,"start":4431,"enrollment":4432,"conditions":4457,"interventions":4458},[87],[4434,4435,4436,4437,4438],[4412,4440],{"intervention":4460,"totalTrials":136,"cells":4461},"0 ul of dexmedetomidine",{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4463,"activeCount":95},[],{"trials":4465,"activeCount":95},[],{"trials":4467,"activeCount":95},[],{"trials":4469,"activeCount":95},[],{"trials":4471,"activeCount":95},[],{"trials":4473,"activeCount":95},[4474],{"nctId":4475,"briefTitle":4476,"status":105,"phases":4477,"primaryCompletion":4478,"completion":4478,"start":4479,"enrollment":22,"conditions":4480,"interventions":4481},"NCT04269278","Dexmedetomidine and Blood Coagulation",[],"2020-12-30","2020-02-12",[3861],[4460,4482,4483,4484],"0.25 ul of dexmedetomidine","0.5 ul of dexmedetomidine","0.75 ul of dexmedetomidine",{"intervention":4482,"totalTrials":136,"cells":4486},{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4493,"PHASE4":4495,"NA":4497},{"trials":4488,"activeCount":95},[],{"trials":4490,"activeCount":95},[],{"trials":4492,"activeCount":95},[],{"trials":4494,"activeCount":95},[],{"trials":4496,"activeCount":95},[],{"trials":4498,"activeCount":95},[4499],{"nctId":4475,"briefTitle":4476,"status":105,"phases":4500,"primaryCompletion":4478,"completion":4478,"start":4479,"enrollment":22,"conditions":4501,"interventions":4502},[],[3861],[4460,4482,4483,4484],{"intervention":4483,"totalTrials":136,"cells":4504},{"EARLY_PHASE1":4505,"PHASE1":4507,"PHASE2":4509,"PHASE3":4511,"PHASE4":4513,"NA":4515},{"trials":4506,"activeCount":95},[],{"trials":4508,"activeCount":95},[],{"trials":4510,"activeCount":95},[],{"trials":4512,"activeCount":95},[],{"trials":4514,"activeCount":95},[],{"trials":4516,"activeCount":95},[4517],{"nctId":4475,"briefTitle":4476,"status":105,"phases":4518,"primaryCompletion":4478,"completion":4478,"start":4479,"enrollment":22,"conditions":4519,"interventions":4520},[],[3861],[4460,4482,4483,4484],{"intervention":4484,"totalTrials":136,"cells":4522},{"EARLY_PHASE1":4523,"PHASE1":4525,"PHASE2":4527,"PHASE3":4529,"PHASE4":4531,"NA":4533},{"trials":4524,"activeCount":95},[],{"trials":4526,"activeCount":95},[],{"trials":4528,"activeCount":95},[],{"trials":4530,"activeCount":95},[],{"trials":4532,"activeCount":95},[],{"trials":4534,"activeCount":95},[4535],{"nctId":4475,"briefTitle":4476,"status":105,"phases":4536,"primaryCompletion":4478,"completion":4478,"start":4479,"enrollment":22,"conditions":4537,"interventions":4538},[],[3861],[4460,4482,4483,4484],{"intervention":2987,"totalTrials":136,"cells":4540},{"EARLY_PHASE1":4541,"PHASE1":4543,"PHASE2":4545,"PHASE3":4547,"PHASE4":4549,"NA":4551},{"trials":4542,"activeCount":95},[],{"trials":4544,"activeCount":95},[],{"trials":4546,"activeCount":95},[],{"trials":4548,"activeCount":95},[],{"trials":4550,"activeCount":95},[],{"trials":4552,"activeCount":95},[4553],{"nctId":2979,"briefTitle":2980,"status":105,"phases":4554,"primaryCompletion":2982,"completion":2982,"start":1049,"enrollment":2983,"conditions":4555,"interventions":4556},[87],[2985],[2987,2977],{"intervention":4558,"totalTrials":136,"cells":4559},"Fentanyl selector",{"EARLY_PHASE1":4560,"PHASE1":4562,"PHASE2":4564,"PHASE3":4566,"PHASE4":4568,"NA":4570},{"trials":4561,"activeCount":95},[],{"trials":4563,"activeCount":95},[],{"trials":4565,"activeCount":95},[],{"trials":4567,"activeCount":95},[],{"trials":4569,"activeCount":95},[],{"trials":4571,"activeCount":95},[4572],{"nctId":4573,"briefTitle":4574,"status":105,"phases":4575,"primaryCompletion":1035,"completion":1035,"start":1034,"enrollment":3639,"conditions":4576,"interventions":4578},"NCT05489796","Bellomic PCA in Laparoscopic Gynecologic Surgery",[87],[4577],"Laparoscopic Gynecological Surgery",[4558,4579,4580],"Fentanyl continuous","Ketorolac continuous",{"intervention":4579,"totalTrials":136,"cells":4582},{"EARLY_PHASE1":4583,"PHASE1":4585,"PHASE2":4587,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4584,"activeCount":95},[],{"trials":4586,"activeCount":95},[],{"trials":4588,"activeCount":95},[],{"trials":4590,"activeCount":95},[],{"trials":4592,"activeCount":95},[],{"trials":4594,"activeCount":95},[4595],{"nctId":4573,"briefTitle":4574,"status":105,"phases":4596,"primaryCompletion":1035,"completion":1035,"start":1034,"enrollment":3639,"conditions":4597,"interventions":4598},[87],[4577],[4558,4579,4580],{"intervention":4580,"totalTrials":136,"cells":4600},{"EARLY_PHASE1":4601,"PHASE1":4603,"PHASE2":4605,"PHASE3":4607,"PHASE4":4609,"NA":4611},{"trials":4602,"activeCount":95},[],{"trials":4604,"activeCount":95},[],{"trials":4606,"activeCount":95},[],{"trials":4608,"activeCount":95},[],{"trials":4610,"activeCount":95},[],{"trials":4612,"activeCount":95},[4613],{"nctId":4573,"briefTitle":4574,"status":105,"phases":4614,"primaryCompletion":1035,"completion":1035,"start":1034,"enrollment":3639,"conditions":4615,"interventions":4616},[87],[4577],[4558,4579,4580],{"intervention":3114,"totalTrials":136,"cells":4618},{"EARLY_PHASE1":4619,"PHASE1":4621,"PHASE2":4623,"PHASE3":4625,"PHASE4":4627,"NA":4629},{"trials":4620,"activeCount":95},[],{"trials":4622,"activeCount":95},[],{"trials":4624,"activeCount":95},[],{"trials":4626,"activeCount":95},[],{"trials":4628,"activeCount":95},[],{"trials":4630,"activeCount":95},[4631],{"nctId":3107,"briefTitle":3108,"status":162,"phases":4632,"primaryCompletion":3110,"completion":3110,"start":1987,"enrollment":1272,"conditions":4633,"interventions":4634},[87],[3112],[2960,3114,3114],{"intervention":4636,"totalTrials":136,"cells":4637},"shampoos and scalp serums",{"EARLY_PHASE1":4638,"PHASE1":4640,"PHASE2":4642,"PHASE3":4644,"PHASE4":4646,"NA":4648},{"trials":4639,"activeCount":95},[],{"trials":4641,"activeCount":95},[],{"trials":4643,"activeCount":95},[],{"trials":4645,"activeCount":95},[],{"trials":4647,"activeCount":95},[],{"trials":4649,"activeCount":95},[4650],{"nctId":4651,"briefTitle":4652,"status":105,"phases":4653,"primaryCompletion":4654,"completion":4655,"start":4656,"enrollment":109,"conditions":4657,"interventions":4660},"NCT06052241","Artificial Intelligence-based Prescription of Personalized Scalp Cosmetics",[87],"2022-01-07","2022-02-07","2021-07-27",[4658,4659],"Dandruff","Folliculitis",[4636],{"intervention":3552,"totalTrials":136,"cells":4662},{"EARLY_PHASE1":4663,"PHASE1":4665,"PHASE2":4667,"PHASE3":4669,"PHASE4":4671,"NA":4673},{"trials":4664,"activeCount":95},[],{"trials":4666,"activeCount":95},[],{"trials":4668,"activeCount":95},[],{"trials":4670,"activeCount":95},[],{"trials":4672,"activeCount":95},[],{"trials":4674,"activeCount":95},[4675],{"nctId":3544,"briefTitle":3545,"status":105,"phases":4676,"primaryCompletion":3547,"completion":3448,"start":3014,"enrollment":852,"conditions":4677,"interventions":4678},[87],[3549,3550],[3521,3552],{"intervention":4680,"totalTrials":136,"cells":4681},"Heparin",{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4686,"PHASE3":4688,"PHASE4":4690,"NA":4692},{"trials":4683,"activeCount":95},[],{"trials":4685,"activeCount":95},[],{"trials":4687,"activeCount":95},[],{"trials":4689,"activeCount":95},[],{"trials":4691,"activeCount":95},[],{"trials":4693,"activeCount":95},[4694],{"nctId":4695,"briefTitle":4696,"status":105,"phases":4697,"primaryCompletion":1882,"completion":1882,"start":1047,"enrollment":2903,"conditions":4698,"interventions":4702},"NCT01522846","Heparin Solution and INTEM\u002FHEPTEM Analysis",[],[4699,4700,4701],"Brain Tumor","Spinal Stenosis","Cerebral Artery Anuerysm",[4680],{"intervention":4704,"totalTrials":136,"cells":4705},"clozapine",{"EARLY_PHASE1":4706,"PHASE1":4708,"PHASE2":4710,"PHASE3":4712,"PHASE4":4714,"NA":4716},{"trials":4707,"activeCount":95},[],{"trials":4709,"activeCount":95},[],{"trials":4711,"activeCount":95},[],{"trials":4713,"activeCount":95},[],{"trials":4715,"activeCount":95},[],{"trials":4717,"activeCount":95},[4718],{"nctId":4719,"briefTitle":4720,"status":162,"phases":4721,"primaryCompletion":1010,"completion":1010,"start":2348,"enrollment":541,"conditions":4722,"interventions":4725},"NCT01398189","F-18 Altanserin PET Study of Patients Receiving Clozapine",[87],[4723,4724],"Schizophrenia","Schizoaffective Disorder",[4704],{"intervention":3253,"totalTrials":136,"cells":4727},{"EARLY_PHASE1":4728,"PHASE1":4730,"PHASE2":4732,"PHASE3":4734,"PHASE4":4736,"NA":4738},{"trials":4729,"activeCount":95},[],{"trials":4731,"activeCount":95},[],{"trials":4733,"activeCount":95},[],{"trials":4735,"activeCount":95},[],{"trials":4737,"activeCount":95},[],{"trials":4739,"activeCount":95},[4740],{"nctId":3243,"briefTitle":3244,"status":105,"phases":4741,"primaryCompletion":3246,"completion":1009,"start":1316,"enrollment":3247,"conditions":4742,"interventions":4743},[87],[31],[3250,3251,1213,3220,3252,3253],{"intervention":4745,"totalTrials":136,"cells":4746},"Rocuronium: PTC(Post-tetanic count) 1~2",{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4753,"PHASE4":4755,"NA":4757},{"trials":4748,"activeCount":95},[],{"trials":4750,"activeCount":95},[],{"trials":4752,"activeCount":95},[],{"trials":4754,"activeCount":95},[],{"trials":4756,"activeCount":95},[],{"trials":4758,"activeCount":95},[4759],{"nctId":4760,"briefTitle":4761,"status":105,"phases":4762,"primaryCompletion":129,"completion":4763,"start":4764,"enrollment":1095,"conditions":4765,"interventions":4767},"NCT03890406","The Effect of Deep Neuromuscular Blockade on Requirement of Intravenous Anesthetic Agent",[87],"2020-03-31","2019-04-01",[4766,1086,27],"Laparoscopy",[4745,4768],"Rocuronium: TOF(Train-of-four) 1~2",{"intervention":4768,"totalTrials":136,"cells":4770},{"EARLY_PHASE1":4771,"PHASE1":4773,"PHASE2":4775,"PHASE3":4777,"PHASE4":4779,"NA":4781},{"trials":4772,"activeCount":95},[],{"trials":4774,"activeCount":95},[],{"trials":4776,"activeCount":95},[],{"trials":4778,"activeCount":95},[],{"trials":4780,"activeCount":95},[],{"trials":4782,"activeCount":95},[4783],{"nctId":4760,"briefTitle":4761,"status":105,"phases":4784,"primaryCompletion":129,"completion":4763,"start":4764,"enrollment":1095,"conditions":4785,"interventions":4786},[87],[4766,1086,27],[4745,4768],{"intervention":4788,"totalTrials":136,"cells":4789},"cetrorelix acetate",{"EARLY_PHASE1":4790,"PHASE1":4792,"PHASE2":4794,"PHASE3":4796,"PHASE4":4798,"NA":4800},{"trials":4791,"activeCount":95},[],{"trials":4793,"activeCount":95},[],{"trials":4795,"activeCount":95},[],{"trials":4797,"activeCount":95},[],{"trials":4799,"activeCount":95},[],{"trials":4801,"activeCount":95},[4802],{"nctId":4803,"briefTitle":4804,"status":105,"phases":4805,"primaryCompletion":4806,"completion":4806,"start":4807,"enrollment":438,"conditions":4808,"interventions":4810},"NCT00571870","Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study",[87],"2009-08","2007-11",[4809],"Infertility",[4788],{"intervention":4812,"totalTrials":136,"cells":4813},"deep neuromuscular blockade",{"EARLY_PHASE1":4814,"PHASE1":4816,"PHASE2":4818,"PHASE3":4820,"PHASE4":4822,"NA":4824},{"trials":4815,"activeCount":95},[],{"trials":4817,"activeCount":95},[],{"trials":4819,"activeCount":95},[],{"trials":4821,"activeCount":95},[],{"trials":4823,"activeCount":95},[],{"trials":4825,"activeCount":95},[4826],{"nctId":4827,"briefTitle":4828,"status":162,"phases":4829,"primaryCompletion":4830,"completion":4830,"start":4831,"enrollment":3155,"conditions":4832,"interventions":4834},"NCT04688268","Dose for Deep Neuromuscular Blockade Deciding Factor of Neuromuscular Blocker Dose for Deep Neuromuscular Blockade",[],"2021-07-30","2021-01-10",[4833],"Laparoscopic Surgery",[4812],{"intervention":4836,"totalTrials":136,"cells":4837},"Citric acid",{"EARLY_PHASE1":4838,"PHASE1":4840,"PHASE2":4842,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4839,"activeCount":95},[],{"trials":4841,"activeCount":95},[],{"trials":4843,"activeCount":95},[],{"trials":4845,"activeCount":95},[],{"trials":4847,"activeCount":95},[],{"trials":4849,"activeCount":95},[4850],{"nctId":4851,"briefTitle":4852,"status":105,"phases":4853,"primaryCompletion":1744,"completion":1744,"start":4854,"enrollment":4855,"conditions":4856,"interventions":4857},"NCT02359942","The Diagnostic Validity of the Urea Breath Test",[87],"2015-03-01",1200,[31],[4836],{"intervention":4859,"totalTrials":136,"cells":4860},"14 day PBMT group",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4865,"PHASE3":4867,"PHASE4":4869,"NA":4871},{"trials":4862,"activeCount":95},[],{"trials":4864,"activeCount":95},[],{"trials":4866,"activeCount":95},[],{"trials":4868,"activeCount":95},[],{"trials":4870,"activeCount":95},[],{"trials":4872,"activeCount":95},[4873],{"nctId":4874,"briefTitle":4875,"status":105,"phases":4876,"primaryCompletion":4877,"completion":4877,"start":1406,"enrollment":4878,"conditions":4879,"interventions":4880},"NCT02349685","The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori",[87],"2014-06",219,[854],[4859,4881],"14 day MEA group",{"intervention":4881,"totalTrials":136,"cells":4883},{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4890,"PHASE4":4892,"NA":4894},{"trials":4885,"activeCount":95},[],{"trials":4887,"activeCount":95},[],{"trials":4889,"activeCount":95},[],{"trials":4891,"activeCount":95},[],{"trials":4893,"activeCount":95},[],{"trials":4895,"activeCount":95},[4896],{"nctId":4874,"briefTitle":4875,"status":105,"phases":4897,"primaryCompletion":4877,"completion":4877,"start":1406,"enrollment":4878,"conditions":4898,"interventions":4899},[87],[854],[4859,4881],{"intervention":4901,"totalTrials":136,"cells":4902},"sildenafil 100mg",{"EARLY_PHASE1":4903,"PHASE1":4905,"PHASE2":4907,"PHASE3":4909,"PHASE4":4911,"NA":4913},{"trials":4904,"activeCount":95},[],{"trials":4906,"activeCount":95},[],{"trials":4908,"activeCount":95},[],{"trials":4910,"activeCount":95},[],{"trials":4912,"activeCount":95},[],{"trials":4914,"activeCount":95},[4915],{"nctId":4916,"briefTitle":4917,"status":162,"phases":4918,"primaryCompletion":1404,"completion":1882,"start":2323,"enrollment":4919,"conditions":4920,"interventions":4922},"NCT01054001","Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy",[87],124,[4921],"Prostate Cancer",[4901],{"intervention":3009,"totalTrials":136,"cells":4924},{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4929,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4926,"activeCount":95},[],{"trials":4928,"activeCount":95},[],{"trials":4930,"activeCount":95},[],{"trials":4932,"activeCount":95},[],{"trials":4934,"activeCount":95},[],{"trials":4936,"activeCount":95},[4937],{"nctId":2998,"briefTitle":2999,"status":162,"phases":4938,"primaryCompletion":3001,"completion":3001,"start":3002,"enrollment":188,"conditions":4939,"interventions":4940},[87],[3004,3005,3006,3007],[3009,2552],{"intervention":4942,"totalTrials":136,"cells":4943},"deep neuromuscular blockade in bariatric surgery",{"EARLY_PHASE1":4944,"PHASE1":4946,"PHASE2":4948,"PHASE3":4950,"PHASE4":4952,"NA":4954},{"trials":4945,"activeCount":95},[],{"trials":4947,"activeCount":95},[],{"trials":4949,"activeCount":95},[],{"trials":4951,"activeCount":95},[],{"trials":4953,"activeCount":95},[],{"trials":4955,"activeCount":95},[4956],{"nctId":4957,"briefTitle":4958,"status":162,"phases":4959,"primaryCompletion":4960,"completion":4960,"start":4961,"enrollment":3155,"conditions":4962,"interventions":4964},"NCT04709406","Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery",[],"2021-10","2021-01",[4963],"Bariatric Surgery",[4942],{"intervention":4966,"totalTrials":136,"cells":4967},"Sex, Age",{"EARLY_PHASE1":4968,"PHASE1":4970,"PHASE2":4972,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4969,"activeCount":95},[],{"trials":4971,"activeCount":95},[],{"trials":4973,"activeCount":95},[],{"trials":4975,"activeCount":95},[],{"trials":4977,"activeCount":95},[],{"trials":4979,"activeCount":95},[4980],{"nctId":4981,"briefTitle":4982,"status":105,"phases":4983,"primaryCompletion":4984,"completion":4985,"start":4986,"enrollment":4987,"conditions":4988,"interventions":4991},"NCT04973631","The Effects of Sex and Age Differences on Gastric Cancer : a Retrospective Study",[],"2021-09","2022-01","2003-05",14900,[4989,4990,18],"Sex","Age",[4966],{"intervention":3037,"totalTrials":136,"cells":4993},{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5002,"NA":5004},{"trials":4995,"activeCount":95},[],{"trials":4997,"activeCount":95},[],{"trials":4999,"activeCount":95},[],{"trials":5001,"activeCount":95},[],{"trials":5003,"activeCount":95},[],{"trials":5005,"activeCount":95},[5006],{"nctId":3027,"briefTitle":3028,"status":105,"phases":5007,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":3032,"conditions":5008,"interventions":5009},[87],[3034,3035],[3037,2977],{"intervention":3047,"totalTrials":136,"cells":5011},{"EARLY_PHASE1":5012,"PHASE1":5014,"PHASE2":5016,"PHASE3":5018,"PHASE4":5020,"NA":5022},{"trials":5013,"activeCount":95},[],{"trials":5015,"activeCount":95},[],{"trials":5017,"activeCount":95},[],{"trials":5019,"activeCount":95},[],{"trials":5021,"activeCount":95},[],{"trials":5023,"activeCount":95},[5024],{"nctId":3039,"briefTitle":3040,"status":162,"phases":5025,"primaryCompletion":3042,"completion":1314,"start":3043,"enrollment":109,"conditions":5026,"interventions":5027},[87],[3045],[3047,1634],{"intervention":5029,"totalTrials":136,"cells":5030},"gemigliptin\u002Fmetformin",{"EARLY_PHASE1":5031,"PHASE1":5033,"PHASE2":5035,"PHASE3":5037,"PHASE4":5039,"NA":5041},{"trials":5032,"activeCount":95},[],{"trials":5034,"activeCount":95},[],{"trials":5036,"activeCount":95},[],{"trials":5038,"activeCount":95},[],{"trials":5040,"activeCount":95},[],{"trials":5042,"activeCount":95},[5043],{"nctId":5044,"briefTitle":5045,"status":105,"phases":5046,"primaryCompletion":5047,"completion":5047,"start":5048,"enrollment":2274,"conditions":5049,"interventions":5050},"NCT02609815","Initial Combination of Gemigliptin and Metformin on Microbiota Change",[87],"2021-03-15","2015-11-01",[21],[5029,5051],"glimepiride\u002Fmetformin",{"intervention":5051,"totalTrials":136,"cells":5053},{"EARLY_PHASE1":5054,"PHASE1":5056,"PHASE2":5058,"PHASE3":5060,"PHASE4":5062,"NA":5064},{"trials":5055,"activeCount":95},[],{"trials":5057,"activeCount":95},[],{"trials":5059,"activeCount":95},[],{"trials":5061,"activeCount":95},[],{"trials":5063,"activeCount":95},[],{"trials":5065,"activeCount":95},[5066],{"nctId":5044,"briefTitle":5045,"status":105,"phases":5067,"primaryCompletion":5047,"completion":5047,"start":5048,"enrollment":2274,"conditions":5068,"interventions":5069},[87],[21],[5029,5051],{"intervention":5071,"totalTrials":136,"cells":5072},"S-1",{"EARLY_PHASE1":5073,"PHASE1":5075,"PHASE2":5077,"PHASE3":5079,"PHASE4":5081,"NA":5083},{"trials":5074,"activeCount":95},[],{"trials":5076,"activeCount":95},[],{"trials":5078,"activeCount":95},[],{"trials":5080,"activeCount":95},[],{"trials":5082,"activeCount":95},[],{"trials":5084,"activeCount":95},[5085],{"nctId":5086,"briefTitle":5087,"status":162,"phases":5088,"primaryCompletion":1404,"completion":1557,"start":5089,"enrollment":199,"conditions":5090,"interventions":5091},"NCT01486472","S-1-induced Lacrimal Drainage Obstruction",[],"2010-11",[18],[5071],{"intervention":5093,"totalTrials":136,"cells":5094},"Bevacizumab",{"EARLY_PHASE1":5095,"PHASE1":5097,"PHASE2":5099,"PHASE3":5101,"PHASE4":5103,"NA":5105},{"trials":5096,"activeCount":95},[],{"trials":5098,"activeCount":95},[],{"trials":5100,"activeCount":95},[],{"trials":5102,"activeCount":95},[],{"trials":5104,"activeCount":95},[],{"trials":5106,"activeCount":95},[5107],{"nctId":5108,"briefTitle":5109,"status":105,"phases":5110,"primaryCompletion":2982,"completion":2982,"start":5111,"enrollment":4363,"conditions":5112,"interventions":5114},"NCT00745498","Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy",[87],"2008-06",[5113,4438],"Proliferative Diabetic Retinopathy",[5093],{"intervention":3262,"totalTrials":136,"cells":5116},{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5121,"PHASE3":5123,"PHASE4":5125,"NA":5127},{"trials":5118,"activeCount":95},[],{"trials":5120,"activeCount":95},[],{"trials":5122,"activeCount":95},[],{"trials":5124,"activeCount":95},[],{"trials":5126,"activeCount":95},[],{"trials":5128,"activeCount":95},[5129],{"nctId":3255,"briefTitle":3256,"status":1879,"phases":5130,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":5131,"interventions":5132},[87],[854],[3262,3220,3252,1225,3263,3264,3251],{"intervention":3263,"totalTrials":136,"cells":5134},{"EARLY_PHASE1":5135,"PHASE1":5137,"PHASE2":5139,"PHASE3":5141,"PHASE4":5143,"NA":5145},{"trials":5136,"activeCount":95},[],{"trials":5138,"activeCount":95},[],{"trials":5140,"activeCount":95},[],{"trials":5142,"activeCount":95},[],{"trials":5144,"activeCount":95},[],{"trials":5146,"activeCount":95},[5147],{"nctId":3255,"briefTitle":3256,"status":1879,"phases":5148,"primaryCompletion":3258,"completion":3258,"start":851,"enrollment":3259,"conditions":5149,"interventions":5150},[87],[854],[3262,3220,3252,1225,3263,3264,3251]]